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Objectives :  
 To study and compare the morphology, size and distribution of CD1a 
positive Langerhans Cells (LCs) in the ectocervical epithelium of the normal 
cervix, carcinoma of cervix and normal cervix associated with other genital 
carcinomas. 
 Methods: 
 
  Normal and cancerous ectocervical tissues, obtained after informed 
consent, from 47 women undergoing hysterectomies, were processed for 
immunohistochemical staining with CD1a marker and studied by light 
microscopy. The morphology and distribution of the CD1a positive LCs were 
studied. The difference in the total number of LCs and different types of 
CD1a positive LCs per mm length of ectocervical epithelium were compared 
between the various groups using the Kruskal Wallis test and between pairs 
of groups using the Mann Whitney U test. The mean diameters of LCs were 
compared between the groups using ANOVA and pairs of groups using the 
Scheffe multiple comparison test. 
  
 Results:  
 
  There were significantly fewer CD1a positive LCs in squamous cell and 
adenocarcinoma of cervix than in normal. An additional previously 
unclassified variety of LCs having no processes was noted and this was the 
predominant type in carcinoma cervix. Cells having single processes were 
significantly higher in normal cervix as compared to cervical carcinomas. 
The diameters of CD1a positive LCs were significantly higher in normal 
cervix than in carcinoma cervix. This data may shed new insights into the 
role of LCs in the disease process of cervical carcinomas.  
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1. INTRODUCTION 
 
 Dendritic cells (DCs) are the most potent, professional, antigen 
presenting cells with the distinctive ability to initiate a primary immune 
response. They are derived from  bone marrow progenitors, which 
circulate in the peripheral blood and then reach peripheral tissues, 
where the immature DCs capture invading antigens  (1). Hence DCs 
continuously monitor their microenvironment and when they come 
across danger signals, they undergo a differentiation and maturation 
process. Maturing DCs usually migrate to lymphoid tissues where they 
present antigens to T lymphocyte to commence a primary immune 
response (2). The maturation of DCs is the important determining factor 
to begin immunity or immune tolerance (3). After entering DCs, 
antigens are processed and broken down into peptides in their cytosol 
and then again expressed on the cell surface of DCs by binding to major 
histocompatibility complex (MHC) proteins. The peptides bound to MHC 
class II molecules interact with CD4 positive T helper lymphocytes 
which results in a profound immune regulatory effect. Similarly, when 
they bind to MHC class I molecules, cytotoxic CD8 positive T 
lymphocytes are activated. They recognise and destroy virus infected 
cells and cancer cells (4). Thus DCs play a key role in host immune 
defences and a crucial role in anti-cancer immune responses (5). 
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 Langerhans cells (LCs), a type of DCs are MHC class II expressing 
bone marrow derived DCs. They mainly present as immature cells on 
different epithelial tissues to detect invading pathogens or foreign 
antigens (6). After antigen uptake these cells undergo a maturation 
process and are capable of initiating primary T lymphocyte mediated 
immune responses in lymph nodes. These cells are known to be present 
in the epidermis (7), oral mucosa (8), oesophagus (9), glottis (10), lung 
(11) tongue (12), larynx (13), cervix (14) and vagina (15). In 1980, 
Figueroa and Caorsi classified LCs in the ectocervix into 5 types based 
on the number of processes they had as follows: type I- those having 
one process, type II- with one process which branched, type III- cells 
with two processes, type IV- those with three or more processes and 
type V- cells having three or more processes but with several collaterals 
(16). 
 Carcinoma cervix is the second most common carcinoma 
affecting women worldwide (17). 70% of cases are caused by human 
papilloma virus (HPV) infections mainly HPV 16 & 18 strains (18). First, 
HPV infected keratinocytes are eliminated by innate immunity resulting 
from epithelial residing LCs and macrophages. If keratinocytes escape 
the innate defence, then cellular immunity takes the role of killing HPV 
infected cells by inducing a systemic response in regional lymphoid 
organs or a local immune response by LCs in the cervix.  Langerhans 
cells play an important role in both innate and cellular immunity by 
acting as antigen presenting cells (19). HPV associated carcinoma cervix 
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can be treated by a virus specific cytotoxic T lymphocyte response 
produced by an autologous DCs vaccination (20). In the development of 
cervical neoplasia, where HPV is confined to the epithelium, the 
presence and maturation of the LCs are vital for the initiation of a 
tumoricidal response against its progression towards increasing grades 
of dysplasia and ultimately invasive cancers (21). 
Role of dendritic cells in carcinoma  
 In carcinomas, immature DCs regularly monitor the environment 
for foreign antigens. Once the DCs encounter any antigen, they engulf 
the same by any one of the following processes, namely, phagocytosis, 
macropinocytosis and endocytosis. This is followed by maturation of 
DCs by down-regulation of endocytic activity. Subsequent migration to 
lymphoid tissue results in efficient presentation of optimally processed 
antigens to T lymphocytes (22). These specified functions of DCs 
including endocytosis, migration and antigen presentation by DCs help 
to maintain adaptive immune responses, including an antitumor 
response against tumour antigens (23). Cytokines like interleukin-10 
(IL-10) and vascular endothelial growth factor (VEGF) that are produced 
by the tumour, inhibit the maturation of DCs (24). The immature cells 
present in and around the tumour, lack the co-stimulatory molecules 
necessary for presentation of tumour cell membrane information to the 
T lymphocytes. Like infectious pathogens, tumours cannot induce the 
inflammatory response necessary for activation of DCs. This results in 
an ineffective immune response and disease progression (25). The 
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number of tumour infiltrating DCs have been found to be clinically 
important because patients with more number DC  infiltration in the 
tumours lived longer than those who had few or absent DCs (7).  
 Although, since the 1980s, there has been a growing interest in 
the study of the distribution and morphometric analysis of LCs in the 
uterine cervix (26), there is a paucity of information regarding their 
distribution and morphology in cervical cancer. By quantifying the LCs 
in cervical carcinomas, it is hoped that more information about the 
effects of neoplastic cells on LCs can be revealed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
2. AIM AND OBJECTIVES 
Aim: 
To study the morphology and distribution of CD1a positive 
Langerhans cells in normal and carcinoma cervix by 
immunohistochemistry. 
 
 
Objectives:  
 
1. To study the morphology of CD1a positive LCs in the 
ectocervical epithelium of the normal cervix, carcinoma of 
cervix and normal cervix associated with other genital 
carcinomas. 
2. To count and compare the number of CD1a positive LCs per 
unit length of ectocervical epithelium in the categories 
mentioned above. 
3. To count and compare the types of CD1a positive LCs per unit 
length of ectocervical epithelium in the categories mentioned 
above. 
4. To measure and compare the diameter of CD1a positive LCs 
present in the ectocervical epithelium in the categories 
mentioned above. 
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3. LITERATURE REVIEW 
 
 
FEMALE GENITAL TRACT 
 The female genital tract is considered to be a part of the common 
mucosal immune system (27). The female genital tract can be divided 
into two compartments, the upper and lower genital tracts. The upper 
genital tract consists of the uterus and Fallopian tubes which are lined 
by simple columnar epithelium and ovaries. The lower genital tract 
includes vagina and vulva which are lined by non-keratinized stratified 
squamous epithelium (28). 
Cervix 
  The cervix is cylindrical in shape and measures about 2.5 cm 
long. The upper third of cervix is called the isthmus. It communicates 
above with the body of the uterus by the internal os. The isthmus 
undergoes changes during the menstrual cycle and pregnancy. Based 
on the projection of external end of cervix into upper vagina, the cervix 
is divided into supravaginal and vaginal parts (28).  
 
Histology of cervix 
 Depending upon the lining epithelium, the cervix can be divided 
into ectocervix and endocervix. The ectocervix is lined by glycogen rich, 
non-keratinized stratified squamous epithelium. The ectocervical 
epithelium is divided into 3 layers each having different cell types. 
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These are from the basement membrane outwards: (1) basal and 
parabasal cell layers, (2) intermediate cell layer, and (3) superficial cell 
layer. The basal cells are responsible for epithelial regeneration and 
parabasal cells shows mitotic figures with a high nuclear-cytoplasmic 
ratio. The thick intermediate layers are formed by mature cells 
containing glycogen. Superficial layers are made up of non-proliferating, 
large, polygonal cells. These cells represent an end stage in the 
maturation process   (29). The cervical canal, lined by highly folded 
mucosa of columnar mucus cells, is called endocervix (28). The 
endocervical mucosa differs from the rest of the uterine endometrium 
the presence of large, branched, mucus secreting cervical glands (30). 
This mucosa does not desquamate during menstruation. Under the 
influence of ovarian hormones during ovulation, these glands secrete a 
watery fluid to facilitate the migration of sperm in the female genital 
tract. In the luteal phase, under the influence of progesterone and 
during pregnancy, this mucus secretion becomes more viscous and 
forms a mucus plug in the cervical canal. This mucus plug prevents the 
entry of sperm and microorganisms into the body of uterus (31). The 
core of the cervix is formed by tough and dense collagen fibres with 
small amounts of smooth muscle (32). Lysis of these collagen fibres 
leads to dilation of cervix before parturition (33). 
Transformation zone    
  The meeting point of the endocervical canal and ectocervix is 
called the transformation zone. A transition between the lining 
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epithelium of the endo and ectocervix happens at this region. In the 
reproductive age group, under the influence of oestrogen, subcolumnar 
reserve cells of the transformation zone proliferate and undergo 
squamous differentiation, thereby replacing existing the endocervical 
columnar glandular epithelium with squamous epithelium (34). The 
transformation zone is present at the external os before puberty. After 
menopause, this region recedes inside the cervical canal due to the lack 
of oestrogen (28). Since 90% of cervical carcinomas arises from this 
zone, it is considered to be the most important landmark for cytology 
and colposcopic examinations (35). In normal conditions, more T 
lymphocytes and antigen presenting cells are seen in the 
transformation zone and its cervical adjacent tissues in contrast to few 
T lymphocytes & antigen presenting cells in the normal vagina (36). 
This region showed higher levels of immunosuppressive agents like 
transforming growth factor beta-1(TGF-β1) & interleukin-10 (IL-10). 
These two agents mediate type-1 T cell responses by interfering with 
antigen presenting cells, thus making this region more vulnerable for 
development of cancer (37).  
 
Diseases of cervix 
 Diseases of the cervix vary from mild inflammation to dysplastic 
and carcinomatous changes. 
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Metaplasia 
 The reserve cells lying deep to the columnar epithelium near the 
transformation zone are transformed into mature squamous cells in a 
process called metaplasia. These metaplastic cells are normal cells with 
no nuclear atypical features and do not turn into cancerous cells. 
However, but in case of atypical metaplasia, cells with abnormal 
nuclear changes lead to dysplasia and malignancy. The causes for 
metaplasia are infection, alteration in pH, hormones and mutagens. 
The hallmark of malignant potential of this cell is presence of  
aneuploidy,  whereas diploidy or polyploidy are present in benign and 
reparatory cells (38). 
 
Dysplasia 
 Dysplasia represents alteration of cell morphology and disorderly 
arranged cells of stratified squamous epithelium with variable size, 
shape and polarity. Thus dysplastic cells show altered nuclear-
cytoplasmic ratios and larger irregular, hyperchromatic nuclei with 
marginal condensed chromatin and mitotic figures (38).  
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Cervical intraepithelial neoplasia (CIN)  
 The term cervical intraepithelial neoplasia denotes a continuum 
of disorders from mild, moderate to severe dysplasia and carcinoma in 
situ. Depending on the replacement of partial or the full thickness of 
the stratified squamous epithelium by dysplastic cells basement 
membrane being intact, cervical intraepithelial neoplasia is classified 
into three grades as follows:  
i. Mild dysplasia (CIN I) 
ii. Moderate dysplasia (CIN II) 
iii. Severe dysplasia (CIN III) (38)  
 
Cancer cervix 
  Carcinoma cervix is the second most common carcinoma 
affecting women worldwide (17).  It is the most common genital cancer 
(80%) incidence in India and  accounts for 15% of all other cancers in 
women (38).  
 The most common histological subtype of invasive cervical 
cancers is squamous cell carcinoma, accounting for 80% of tumours. 
Other types include adenocarcinoma (15%) while other rare types like 
adenosquamous carcinoma and neuroendocrine tumours constitute the 
remaining 5%. All types are caused by highly oncogenic HPV. The peak 
incidence age for carcinoma cervix is 45 years. There is a prolonged 
duration of precancerous lesion preceding most of the cancers. This 
11 
 
makes the cytological screening effective in preventing invasive 
carcinomas (39).  
Squamous cell carcinoma of cervix (SCC) 
 Squamous cell carcinoma of cervix is a malignant neoplasm 
derived from the stratified squamous epithelium lining the ectocervix. 
According to the modified Broder’s system, squamous cell carcinomas 
of cervix are classified as well differentiated, moderately differentiated or 
poorly differentiated based on the degree of nuclear pleomorphism, 
mitotic figures, and keratinisation observed (34). However, a weakness 
of this system is the poor correlation between grade and prognosis (40). 
Morphological heterogeneity may present even in the same sample due 
to variable cell types, differentiation, growth patterns, degree of 
cytological atypia and keratinisation. With increased mitotic activity 
tumour cells infiltrate in various forms such as anastomosing tracts, 
nests, groups, compact or irregular sheets (34). Two types of tumour 
growth are noted normally, they are fungating (exophytic) and 
infiltrative types (39).  
Adenocarcinoma of cervix 
 Adenocarcinoma of cervix is a malignant neoplasm consisting 
chiefly of glandular epithelium, with foci of squamous neoplastic cells. 
Proliferation of endocervical glandular epithelial cells having large, 
hyperchromatic nuclei and cytoplasm devoid of mucin gives darker 
appearance to the glands when compared with normal endocervical 
epithelium (39). 
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Risk Factors 
 70% of cervical cancers are caused by high risk human papilloma 
virus (18). 
Human papilloma virus 
 Human papilloma virus is the main causative agent for 
development of squamous cell carcinoma of cervix. Route of 
transmission is mainly genital skin to skin contact. HPV is classified 
into mucosa associated low risk and high risk groups. Low risk groups 
are mainly HPV 6 and11. They induce genital warts and self limiting 
CIN I, whereas high risk group viruses namely HPV 16 and 18 cause 
CIN II, III or invasive cancer by suppressing genes like p53 and pRb 
retinoblastoma genes (35). Initially, HPV infection is eliminated with the 
help of innate immunity produced by epithelial residing LCs and 
macrophages. When this fails, cellular immunity plays an important 
role in controlling HPV infection by the DC derived systemic immune 
response in lymph nodes (19).   
  Other risk factors include sexual activity less than 18 years, 
multiple sexual partners, long term use of oral contraceptive pills, 
family history of cervical cancer, preinvasive lesions, history of  sexually 
transmitted infections like Chlamydia, genital herpes or HIV,  tobacco 
smoking, immunocompromised conditions like human 
immunodeficiency virus (HIV), chemotherapeutic or steroidal use drug, 
history of transplantation, history of  maternal intake of 
diethylstilbestrol, low socioeconomic status leading to poor health care 
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and diets deficient in beta-carotene, selenium, vitamins  A,E,C and 
folate (41). Tobacco smoking increases the risk of squamous cell 
carcinoma but not adenocarcinoma (42). 
Carcinoma cervix staging based on TNM and FIGO classification 
TNM FIGO Description 
TX  Primary tumour cannot be assessed 
T0  No evidence of primary tumour a 
T1 I Tumour confined to cervix 
T1ab IA 
Invasive carcinoma diagnosed only by microscopy. 
Stromal invasion with a maximal depth of 5mm 
measured from the base of the epithelium and a lateral 
spread of 7mm or lessc 
 
T1a1 IA1 
Measured stromal invasion ≤ 3mm in depth and ≤ 7mm 
lateral spread. 
T1a2 IA2 
Measured stromal invasion  3mm and < 5mm with a 
lateral spread of 7mm or lessd 
T1b IB 
Clinically visible lesion confined to the cervix or 
microscopic lesion greater than T1a/IA2. 
T1b1 IB1 Clinically visible lesion ≤ 4cm in greatest dimension 
T1b2 IB2 Clinically visible lesion  4cm in greatest dimension 
T2 II 
Tumour invades beyond uterus but not to pelvic wall or 
to lower third of vagina 
T2a IIA Tumour without parametrial invasion 
T2a1 IIA1 Clinically visible lesion ≤ 4cm in greatest dimension 
T2a2 IIA2 Clinically visible lesion > 4cm in greatest dimension 
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a FIGO no longer includes stage 0 (Tis). 
b 
All macroscopically visible lesions regardless of superficial 
invasion are T1b/1B. 
c 
Involvement of vascular space or lymphatic, does not affects the 
classification. 
d 
Invasion is restricted to a measured stromal invasion with a 
maximal depth of 5 mm and lateral extension of ≤ 7mm. Depth 
of invasion ≤ 5mm taken from the base of the epithelium. The 
depth of  invasion should always be reported in millimetres. 
e 
On rectal examination, there is no carcinoma-free space 
between the tumour and the pelvic wall. All cases with 
hydronephrosis or non-functioning kidney are included, unless 
with other known causes. 
f Bullous oedema is insufficient to classify a tumour as T4.  
g 
Biopsy-proven involvement of bladder or rectal mucosa 
according to FIGO (34). 
 
T3 III 
Tumour extends to pelvic wall, involves lower third of 
vagina, causes hydronephrosis or non-functioning 
kidneye 
T3a IIIA Tumour involves lower third of vagina 
T3b IIIB 
Tumour extends to pelvic wall, causes hydronephrosis 
or non-functioning kidney 
T4 IVA Tumour extends beyond true pelvisf,g 
M1 IVB Tumour spread to distant organs 
NI  
Regional 
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DENDRITIC CELLS 
 Dendritic cells are potent antigen presenting cells that elicit 
immune responses by presenting antigens to naïve T cells (43). In 1973, 
Steinman and Cohn discovered  highly branched, motile cells in mouse 
splenic tissue under phase-contrast light microscopy and named them 
dendritic cells (44). These cells were named so because of their surface 
projection resembling the dendrites of neurons (43). 
Development  
 The bone marrow, human umbilical cord blood and peripheral 
mononuclear blood cells are the main sources of progenitor cells (45). 
Bone marrow derived DCs originate from cluster differentiation 34 
(CD34) positive haematopoietic stem cells (46) 
Subsets 
 Human dendritic cells contain several phenotypically and 
functionally distinct subpopulations (47). 
 
I. Based on their stage development: (23) 
1. Immature DCs 
2. Mature DCs 
II. Based on their anatomical location: 
1. Circulation DCs – DCs and their precursors comprise 1% of 
mononuclear cells. 
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2. Non-lymphoid tissues DC  derived from blood DC precursors 
include: 
a. Resident DCs – Langerhans cells 
b. Dermal DCs – in the skin 
c. Interstitial DCs – on organs such as liver, lung, kidney and 
heart 
d. Mucosal DCs – in the oral cavity, respiratory and digestive 
tracts (1,48)   
3. Lymphoid DCs  
III. Based on their origin 
1. Myeloid/ conventional  DCs- Blood monocytes are stimulated to 
produce myeloid DCs (MDCs)  in the presence of granulocyte 
macrophage colony stimulating factor (GM-CSF) and IL-4 (49). 
 MDCs express CD11c as their classical marker. They 
induce T helper 1(Th 1) responses (47).  
2. Lymphoid / plasmacytoid DCs-  Plasmacytoid DCs (PDCs) express 
high level of CD123 (IL-3 receptor α-chain) as their surface 
marker (50). These PDCs, apart from stimulating Th2 response, 
also  produce the most potent antiviral cytokine,  interferon 
alpha (IFN-α) (47). PDCs are  found in the thymic medulla and 
areas of T lymphocytes and responsible for immune  tolerance 
(45). 
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IV. Types of Dendritic cells based on their various forms: 
 1. Langerhans cells- These have been described in detail below 
 
 2. Veiled cells- the migrant form of DCs in afferent lymphatics 
       (48). 
 3. Interdigitating cells- the dendritic cells present in the para 
     cortical T lymphocyte regions of lymph nodes. These cells      
     resemble DCs in their morphology (51).  
 4. Follicular dendritic cells- the dendritic cells present in the B cell 
     area of lymphatic follicles are called follicular dendritic cells (1). 
   These cells play an important role in the humoral immunity by 
   inducing B cell proliferation, selection and differentiation (52). 
LANGERHANS CELLS  
 In 1868, Paul Langerhans first described the cells with dendritic 
process during analysis of gold chloride stained human epidermal skin. 
In due course these cells were named Langerhans cells. (53). They are 
the predominant antigen presenting cells in  epithelia especially in 
areas lined by stratified squamous epithelium  like epidermis, 
oesophagus and cervix (54). They play an important role in host 
protection by acting as adjuvants and conductors of immune responses 
against infectious agents and  neoplastic changes (55). 
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LCs ultrastructure 
 Under electron microscopy, LCs display indented nuclei and their 
cytoplasm contains free ribosomes, mitochondria, rough endoplasmic 
reticulum, golgi apparatus, lysosomes, centrioles and the LC specific 
Birbeck granules. Tonofilaments and desmosomes are absent (56). The 
unique feature to confirm LCs under electron microscope is the 
presence of Birbeck granules (57).  
Birbeck granules 
 Langerhans cells differ from the rest of the DCs by the presence 
of rod or tennis racket-shaped Birbeck granules. These membranous 
granules were first discovered by Birbeck in 1961 (53). Birbeck granules 
acquire a cross striated appearance due to the peculiar arrangement of 
electron dense particles within them. Frequently, a rod-shaped 
structure has a vesicle attached at one end giving the appearance of a 
tennis racket. These Birbeck granules are found mainly near either  the 
Golgi apparatus or the plasma membrane, but also seen in the other 
regions of the cytoplasm and in their dendritic processes (58). Langerin 
is associated with Birbeck granules. Induction of Birbeck granules is a 
consequence of the antigen-capturing function of  Langerin, allowing 
routing into these organelles and providing access to the antigen 
processing pathway (59). 
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Demonstration of LCs 
 Inability to demonstrate the LCs by routine eosin and 
haematoxylin staining procedures resulted in employment of special 
techniques like histochemistry, enzyme histochemistry, electron 
microscopy and immunohistochemistry. 
1. Histochemical method 
 Langerhans cells were identified for the first time under 
light microscopy Paul Langerhans by using gold chloride 
impregnation method. The zinc iodide- osmium (ZIO) method has 
been successfully used for the demonstration of LCs under both 
light and electron microscopy (26). Quinine imine dyes such as 
methylene and cresol blue have also used, but these dyes are not 
specific for LCs (60).  
2. Enzyme histochemistry 
The most commonly used enzyme for this method is 
adenosine triphosphatase (ATPase) but this enzyme is membrane 
specific rather than cell specific. This enzyme is present in 
various tissues like those of the nervous system, kidney, liver, 
bladder and cells like keratinocytes, melanocytes, blood cells and 
fibroblasts. Thus because of its non specificity and variability, 
enzyme histochemistry is rarely used to locate LCs (60). 
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3. Electron microscopy 
The gold standard used to confirm the presence of LCs is 
electron microscopy. This method is used to demonstrate the LC 
specific Birbeck granules (60). 
4. Immunohistochemistry 
Langerhans cells are identified mostly based on their 
specific surface antigenic markers. The various immunomarkers 
used are S-100 protein (61), CD1a, langerin (62), vimentin and 
HLA-DR (63). Of these, CD1a is the most specific and sensitive 
marker for immature LCs (64,65). 
 
CD1a 
 The cluster differentiation 1 (CD1) family of human antigens has 
four components namely, CDla, CDlb, CDlc and CD1d which are 
characteristic of the cortical immature thymocytes (66). Of these CD1a 
is a cell surface glycoprotein that is structurally related to MHC 
molecules (64) and was initially named T6 (67,68). LCs express CD1a 
molecules at exceptionally high levels and it is considered to be the 
most specific and sensitive marker for LCs (64).  
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Functions of Langerhans cells 
 Dendritic cells are the most effective antigen presenting cells to 
initiate primary immune responses. Their functions include- 
 1. Capture and process of antigens at surveillance sites 
 2. Initiation and regulation of T lymphocyte and B lymphocyte 
      response by migration to lymphoid organ 
 3. Minimising autoimmune reactions by creating T lymphocyte 
      tolerance to self-antigens (45).  
 
Antigen capture 
 The initiation and propagation of immune responses mainly 
depend on the ability of DCs to capture antigens. Immature DCs are 
efficient to do this function via pinocytosis, endocytosis by using C type 
lectin receptors and phagocytosis (45). Immature DCs are also capable 
of phagocytosing necrotic or apoptotic antigenic particles and cross 
presenting them via major histocompatibility I to cytotoxic T 
lymphocytes (69).  
 
Antigen processing and presentation 
   Immature DCs, after capturing antigens, convert antigenic 
proteins into peptides, load them on intracellular major 
histocompatibility complex I or II, and finally deliver these peptide-MHC 
complexes to the plasma membrane (Figure 1).  Phagocytosed 
extracellular antigens form peptide-MHC II complexes with 
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costimulatory molecules and present them to CD4 positive T 
lymphocytes. The peptide-MHC I complexes bind with CD8 positive T 
lymphocytes to induce cytotoxic effects (70).  
 
 
 
    
Figure 1: A schematic picture depicting the process of antigen 
uptake, processing and presentation by a LC (71) 
 
 
 
 
Migration  
 DCs, after capturing antigens migrate via blood vessels, afferent 
lymphatics or high endothelial venules to reach lymphoid organs and 
present the antigens to lymphocytes for initiation of an immune 
response (72). 
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Maturation  
 
 The maturation process is initiated once the DCs capture 
antigens and is completed during dendritic cell-lymphocyte interaction 
(45). Bacteria and their products namely lipopolysaccharides, 
inflammatory mediators such as tumour necrosis factor-alpha (TNF-α), 
and interleukin-1 stimulate DC maturation. DCs undergo phenotypical 
changes during maturation as follows: 
 loss of receptors responsible for endocytosis and 
phagocytosis 
 enhancement of costimulatory molecules and chemokine 
receptor 7 to induce migration 
 strong expression of peptide-major histocompatibility I or II 
complexes (73). 
 
 
Apoptosis 
  
 Programmed cell death characterized by activation of an 
endonuclease enzyme to  destroy the nucleus is called apoptosis. 
Unless DCs receive survival signals from T lymphocytes, they are 
destroyed rapidly in the T lymphocyte area of lymphoid tissues. 
Activated T lymphocytes could increase DC lifespan in vivo by 
regulating their expression of the antiapoptotic Bcl-x molecule (74). 
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LANGERHANS CELLS IN THE CERVIX   
 Younes et al (75) and Hackeman et al (76), demonstrated  LCs in 
the cervix under electron microscopy for the first time in 1968. 
Hackeman et al., noted a few basal and suprabasal clear cells without 
desmosome attachments in the normal cervix similar to the 
morphological features of  LCs described earlier (76). Figueroa and 
Caorsi described the morphology of LCs and measured their density per 
unit area. This density was much lower than that found in normal 
human epidermis. They stated that their distribution distribution was 
uneven but cells appeared to be preferentially located in the vicinity of 
the external os. They also described their ultrastructure in the normal 
ectocervix.  They proposed that different types of LCs found in the 
normal human ectoocervix represent different degrees of antigenic 
stimulation of the cells at the moment of fixation. Those with the largest 
number of processes, and therefore with the largest surface, might 
contain a large number of surface receptors and so display a high 
antigen-binding activity. In normal human ectocervix the most frequent 
types of LCs were those with few processes, whereas cells with highly 
branched processes were rare (26).  
 In 1983, HLA-DR expressing Langerhans-like cells were 
demonstrated in the ectocervix and vaginal epithelium (15). The 
presence of LCs in the normal epithelium of the ectocervix and 
transformation zone was confirmed in the same year (14). Vargas et al., 
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in 1989, studied LCs in cervix by using T6 and HLA-DR and these cells 
were confirmed to be LCs by the presence of Birbeck granules under 
electron microscopy. They also found that LCs were associated with T 
lymphocytes both in the epithelium and in the lamina propria by using 
a T8 lymphocyte specific marker. The electron micrographs disclosed 
that both LCs and T lymphocytes occupy the intercellular channels of 
the cervical epithelium. It was proposed that in the cervix, LCs function 
as antigen presenting cells for T lymphocytes in normal physiological 
conditions (77). Morelli et al., described the density and distribution of 
LCs in the normal cervix in 1992. He reported that the density of LCs 
increased towards the basement membrane and the dendritic aspect 
was more prominent in the superficial layers (78).  
 
 It has been reported that in pregnant women and smokers the 
number of LCs in the normal squamous epithelium of the 
transformation zone is less (79). Other authors reported decreased 
number of OKT6 positive LCs in cervix with HPV lesions. During follow 
up it was noted that the number of LCs was less in HPV progressed 
cases when compared to HPV persistent lesions. This study highlighted 
the role of dendritic cells against viral infections (80). One study 
analysed MDC and PDC populations in the cervical mucosa and 
peripheral blood of Chlamydia positive women. In their study, healthy 
controls had significantly lower numbers of MDCs and PDCs in their 
cervical sample as compared to Chlamydia positive groups (81).  
   
26 
 
 A study of CD1a positive LCs in different cervical conditions 
revealed the presence of a relatively high number of LCs in both normal 
ectocervix and mature squamous metaplastic epithelium, high number 
of LCs in subcolumnar reserve cell hyperplasia and immature 
squamous metaplasia but a low number of LCs in endocervical 
columnar epithelium and in cases of dysplasia (82). A decreased 
number of  LCs was noted in CIN I lesions and it was proposed that 
there was a decrease in epithelial cell-mediated immune response in 
women with low grade CIN (79). Others reported an increase in the 
more ramified types of LCs in cervical intraepithelial neoplasia and 
invasive carcinomas (83,84).   
 A study quantifying S-100 positive LCs in invasive squamous cell 
carcinoma of cervix and interdigitating, follicular dendritic cells in 
obturator lymph nodes showed that the number of LCs in situ in 
infiltrating carcinoma increased significantly as compared with control 
groups. There was no change in LC numbers between grades II and III 
of squamous cell carcinoma. The results suggested that progression of 
cervical carcinoma was closely related to decrease in LCs in situ and 
interdigitating dendritic cells in the regional lymph nodes (54). 
LCs in carcinomas 
 Langerhans cells play a vital role in the primary immune 
response to carcinoma. Tumour-infiltrating LCs have been found to be 
clinically significant in many human malignancies such as carcinomas 
of the colon, stomach, lung, breast, liver and gall bladder (85). The 
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function of LCs in tumour conditions includes the following steps in 
order:  
   a. Immature LCs identify and capture tumour antigens by   
     endocytosis. 
 b. Activated LCs convert into their mature form, with loss of    
     endocytotic activity. This is accompanied by accumulation of 
     non-specific cells like  eosinophils, natural killer cells and    
     macrophages.  
 c. By up-regulating MHC complexes, LCs present the processed 
     tumour antigens to CD4 and CD8 positive T lymphocytes.  
 d. Antigen specific T lymphocytes are activated and proliferate. 
 e. Finally, these lymphocytes migrate towards the tumour site to 
      kill the transformed cells.    
 This mechanism is responsible for spontaneous regression of 
human cancers in some people by maintaining adaptive immunity for 
anti-tumour response (86). Alteration in any one of these steps can lead 
to tumour progression. Apart from infections other factors like stress, 
therapeutic treatment by chemo and radiotherapy, and surgical 
procedures procedures prevent LC differentiation and activation in 
cancer patients by producing glucocorticoids, catecholamines, 
cytokines & chemokines (55).  
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 Although LCs normally have anti-tumour activity, in cancerous 
lesions they are malfunctioned and polarized into immunosuppressive 
or tolerogenic regulatory LCs, resulting  in tumour progression (87).  
 Tumour induced inhibition of IL-6, macrophage colony 
stimulating factor mediated LC differentiation from monocytes and 
stimulation of monocyte differentiation into macrophages affects the 
antigen presenting function of LCs. Thus tumours can prevent priming 
of tumour-specific T lymphocytes by LCs (24).  
 Tumour derived factors like IL-10 and VEGF help in tumour 
progression by inhibiting LC maturation (24,45). The immature LCs in 
and around the tumours lack the expression of the costimulatory 
molecules which are essential to hand over information of the tumour 
cell membrane to T lymphocytes. Unlike infectious pathogens, tumours 
fail to induce an effective inflammatory response to optimize LC 
activation resulting in a weak immune response (25) 
 In cancer patients there is uptake of extracellular lipids and this 
gets accumulated inside the DCs. These lipid laden LCs decline in their 
capacity to process  encountered tumour antigens or to induce naïve T 
cells but their capacity to express major histocompatibility complex and 
co-stimulatory products is not affected (88). DCs/LCs induce cytotoxic 
effect against HPV 16 envelop proteins E6 & E7 and target cervical 
epithelial cells. This effect is mediated by the pro-inflammatory cytokine 
molecule IFN-gamma, stimulating the expression of Tumour necrosis 
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factor-related apoptosis inducing ligand (TRAIL) on target cervical 
epithelial cells (89). Dysfunction of LCs in patients with cancer is due to 
accumulation of immature cells and reduction in mature competent 
LCs, especially in the blood and lymph node. This effect is mainly 
produced by pooling of myeloid derived immature cells in different 
stages of differentiation (36). 
LCs in other squamous cell carcinomas 
 An increased number of LCs has been reported in benign 
epidermal tumours (90). However contradictory findings regarding the 
presence and the number of LC have been reported in squamous cell 
carcinomas both of cutaneous and mucosal origins (7,90–92).  
Oral carcinoma 
 A comparative study of the number of LCs in normal oral 
epithelium, oral epithelial dysplasia (OED) and oral squamous cell 
carcinoma (OSCC) revealed less LCs in increasing grades of both OED & 
OSCC groups when compared with the normal. More LCs were found 
predominantly in the basal and suprabasal regions in OED but towards 
the surface in OSCC. In all grades of OSCC, there were less LCs in the 
subepithelial area.  This could be due to migration of cells towards 
tumour stroma. The advanced cases of poorly differentiated OSCC 
showed very few LCs in the stroma as well as overlying epithelium 
above it (8).  
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Squamous cell carcinoma of oesophagus 
A study investigating HLA-DR and S-100 positive LCs in 59 
human oesophageal squamous cell carcinomas showed a dense 
infiltration of both type of LCs was detected in 11, only HLA-DR positive 
LCs in two, and only S100 positive LCs in one specimen. In the 
remaining 45 tumours infiltrating LCs were sparse, groups with dense 
infiltration of LCs had better survival rates compared to those with 
sparse infiltration (9). In another study by the same author on the 
distribution of HLA-DR positive LCs and tumour infiltrating 
lymphocytes in 67 patients with squamous cell carcinoma of the 
oesophagus, HLA-DR positive LCs were chiefly present among the 
cancer cell nests, and a few were noted in the stroma. T lymphocytes 
were detected as clusters in the tissue around the cancer cell nests and 
as individual cells within the tumour nests. T lymphocytes in the 
tumour nests showed direct contact with HLA-DR positive LCs. A 
correlation was demonstrated between the number of HLA-DR positive 
LCs and T lymphocytes in each patient. In addition, dense tumour 
infiltration by both LCs and T lymphocytes was associated with a better 
prognosis (93). 
Squamous cell carcinoma of tongue 
 A retrospective study of 43 case of primary squamous cell 
carcinoma of tongue was conducted to determine whether survival and 
recurrence rates correlate with the degree of LCs infiltration in the 
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primary tumour and in tissues adjacent to the tongue. In addition, 
relation between tumour and nodal stage with LCs infiltration was 
studied. Patients who had greater numbers of CD1a positive LCs 
adjacent to the tumour had better survival and decreased recurrence 
rates. The other subpopulations of LCs examined were not associated 
with survival or recurrence. In addition, the number of CD1a positive 
LCs in the peritumoral epithelium decreased as the tumour stage 
increased and if nodal metastases were present. Results of this study 
showed the association between CD1a positive peritumoral LCs and 
patient outcome, suggesting an important role of  CD1a positive LC 
populations in squamous cell carcinoma of tongue (12). 
Squamous cell carcinoma of glottis 
 CD1a positive and S100 positive LCs in 111 specimens of glottic 
squamous cell carcinoma were studied retrospectively. Correlations of 
CD1a positive LCs to pathologic degree, T stage, local recurrence and 
prognosis were analyzed. Positive rates of CD1a positive LCs were 
observed in well differentiated, T1-T2 stage and non recurrent groups 
when compared to moderate and poorly differentiated groups, T3-T4 
stage and groups with local recurrence. High expression of LCs was 
associated with better prognosis (10,94). 
Laryngeal carcinoma 
 S-100 positive and CDla positive interdigitating cells were found 
in the peritumoral infiltrate of 18 patients with squamous cell 
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carcinoma of the larynx. Under electron microscopy, these cells had 
intimate contacts with lymphocytes. They played a role in setting up a 
T-cell immune reaction against neoplastic cells (95). CD1a positive LCs 
were studied in 50 primary laryngeal squamous cell carcinomas, 10 
specimens with metastasis and three samples with recurrence samples. 
Although statistical associations between number of LCs and clinical-
pathological parameters or survival were not found in this study, the 
number of LCs was increased in patients with marked infiltration of 
lymphocytes, mainly cytotoxic T cells (13). 
 
Squamous cell carcinoma of skin 
 A marked increase was found in the number of LCs in seborrheic 
keratoses, an epidermal benign condition, studied by transmission 
electron microscopy (90). The number and morphology of LCs were 
investigated in the epidermal squamous cell carcinomas of sun-exposed 
skin in 10 patients using ATPase as a marker. There was no apparent 
difference between the numbers of LCs in sun-exposed vs. unexposed 
skin from the same individual. A significant decrease in the number of 
LCs was observed.  These LCs exhibited round or oval rather than 
highly dendritic morphology (7). 
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LCs in other tissues with adenocarcinoma 
Breast Carcinoma 
  The presence of immature and mature LCs was shown in 32 
specimens with adenocarcinoma of breast adenocarcinoma specimens. 
In all the specimens, CD1a positive immature LCs were retained in the 
tumour area whereas CD83 positive mature cells were located in the 
peritumoral area in 20 specimens (96). A study of the number of CD1a 
positive LCs within the lymphoid infiltrate of fifty two ductal breast 
carcinoma specimens, noted the number of LCs was less in comparison 
with other cells like macrophages and T cells in most cases (97). Others 
reported that both LC numbers and dendritic cell activation were 
deficient in human breast cancers, regardless of histological grade of 
tumour (98).   
Lung Carcinoma 
 LCs were demonstrated by using S-100 marker in 90 lung 
carcinomas. S-100 positive LCs were observed more frequently in type II 
alveolar cell type compared to goblet cell type adenocarcinomas. In 
addition, small numbers of LCs were noted in a few squamous cell 
carcinoma & large cell carcinomas (99). A study of 46 specimens of lung 
adenocarcinomas using S-100 as a marker showed high LCs infiltration 
in19 specimens with slight infiltration of LCs in the remaining 27. The 5 
year survival rates of these two groups were calculated as 61% & 21% 
respectively. This study concluded that the prognosis of lung 
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adenocarcinoma is better in the markedly infiltrated LCs group when 
compared to the slightly infiltrated group (100) 
Colorectal carcinoma 
 CD83 and CD1a positive LCs were studied in twenty colorectal 
adenocarcinoma specimens. It was noted that CD83 positive mature 
LCs were presented as clusters along the invasive tumour stromal 
margin whereas CD1a positive cells were present scattered rather than 
in clusters, all over the tumour tissue. However their numbers were the 
same as CD83 positive cells in the tumour margin (101). It was noted 
that the infiltration of more than 30 S100 positive LCs in 10 high power 
fields showed better prognosis when compared to cases with lower 
infiltration, without metastasis (102).  
Gastric carcinoma 
 S-100 positive LCs and anti-lysozyme antibodies were 
demonstrated in 174 cases of gastric carcinoma. LCs were mainly 
interspersed among the tumour cells, whereas macrophages were 
present in the stroma and around the necrotic foci. Cases with a 
marked infiltration of LCs, had longer survival time when compared 
with cases with slight infiltration (103). 
Thyroid carcinoma 
 It was observed that in the thyroid gland, compared to follicular 
carcinomas, papillary carcinomas contained marked infiltration of 
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CD1a positive LCs, IL-1α and TNF-α positive cells. More LCs were noted 
in tumour areas and interdigitating cells were seen around the tumour 
areas along with LCs. Cancer cells producing IL-1α and TNF-α 
controlled the infiltration and maturation of LCs. This process was 
maintained in papillary carcinoma in contrast to follicular carcinoma. 
This study revealed that thyroid carcinomas with dense infiltrations of 
LCs were correlated with a favourable prognosis (69).  
 The above studies reveal that, LCs present in tumour areas of 
both squamous and adenocarcinomas of different tissues is directly 
associated with prognosis. 
HIGH ENDOTHELIAL VENULES AND LCS 
 High endothelial venules (HEVs) are specialized postcapillary 
venules lined by cuboidal endothelial cells, bulging into the lumen. 
HEVs are present in secondary lymphoid organs, except the spleen 
(104). DCs have been seen around the walls of HEVs and are important 
for maintaining HEVs characteristics (105).  HEVs control the 
extravasation of naive lymphocytes from the blood into the afferent 
lymphatics through which they reach the secondary lymphoid organs 
(106). This migration of naïve T and B lymphocytes through the HEVs is 
limited by LCs especially CD11c positive cells. This event is mediated by 
lymphotoxin derived from the CD11c positive cells (105). Naïve T and B 
cells migrate through HEVs by the following steps namely rolling, 
sticking, crawling and transmigration. Finally, naïve T and B 
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lymphocytes reach the paracortex and lymphatic follicles respectively 
(104). Solid tumours like breast, colon, lung, ovarian carcinomas and 
melanomas contain vessels similar to HEVs in their stroma. The 
tumour induced HEVs were associated with increased level of B and T 
lymphocyte infiltration and good prognosis carcinoma of breast (104). 
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   4. MATERIALS AND METHODS 
4.1 COLLECTION OF SPECIMENS 
 Ethical approval from the Institutional Review Board, Christian 
Medical College, and Vellore was obtained for the study. 
 
Sample size estimation 
 The sample size calculation was done based on data available 
from a previous study (Hayati and Zulkarnean, 2007: Mean in normal 
group = 3.89 ± 2.63 and squamous cell carcinoma mean = 2.32 ± 1.74) 
(21). The required sample size to show a difference of 2 units in CD1a 
positive Langerhans cells between normal and squamous cell 
carcinoma with 80% power and 5% alpha error was found to be 35 
specimens in each group. 
 
 
 
 
 
 
 
 
 
 
 
Standard deviation in group  I 3 
Standard deviation in group  II 3 
Mean difference 2 
Effect size 0.666667 
Alpha error (%) 5 
Power (1- beta) % 80 
1 or 2 sided 2 
Required sample size per group 35 
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 Formula: 
(Zα+Z1-β) 2 x 2 x S2 
    n = _______________ 
     d 2 
S- Standard deviation, d- 2, Zα- 5% level of significance,  
Z1-β– 80% power of the study 
Inclusion criteria 
 Women undergoing total abdominal hysterectomy in OG I unit for 
conditions like fibroid uterus, endometriosis, adenomyosis, 
carcinoma cervix, carcinoma endometrium and ovarian 
carcinomas. 
Exclusion criteria 
 Immunocompromised patients (e.g. HIV) 
 Patients who have undergone chemotherapy and radiation 
 Patients unwilling to participate in this study 
 
Specimen collection 
 Cervix specimens were collected from patients who underwent 
total abdominal hysterectomy, either from the Department of Obstetrics 
and Gynaecology or from the Department of Pathology, Christian 
Medical College, Vellore. Cervix with intact epithelium of about 1-2 cm 
was collected in neutral formalin. In cases of cancer cervix, for the 
quantitative analysis, tissue away from the tumour area was used. The 
consent was taken from the participated patients in this study, a day 
before surgery in the gynaecology ward. 
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4.2 GROUPING OF COLLECTED SPECIMENS 
 The ectocervix specimens collected were categorized into five 
groups based on their histopathological diagnosis. 
i. Normal cervix – 22 
ii. Cervical Intraepithelial Neoplasia I – 2 
iii. Squamous cell carcinoma of cervix – 11 
iv. Adenocarcinoma of cervix – 4 
v. Normal cervix associated with other genital 
carcinomas – 8 
4.3 FIXATION AND PROCESSING OF TISSUES 
 
Trimmed cervical specimens were fixed in neural formalin for 
about 7- 10 days to prevent autolysis. Excess formalin was removed by 
placing the fixed tissues under running water. Tissues were dehydrated 
by using ascending grades of isopropyl alcohol (70%, 80%, 90%, 95% 
and 100%) followed by clearing in toluene, impregnation with molten 
paraffin wax and embedding in paraffin. 
 
4.4 SECTIONING 
 Five micron thick serial sections were taken using a rotary 
microtome. The serial sections were allowed to float in the hot water 
bath at 45°C and mounted on pre-cleaned slides coated with poly-L-
lysine (PLL).  Slides were air dried, incubated at 37°C overnight and 
stored in clean slide boxes for staining. 
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4.5 STAINING 
 Haematoxylin and eosin staining 
Representative sections at regular intervals were stained by the 
standard haematoxylin and eosin (H & E) staining technique. 
 
Immunohistochemical staining 
 Two slides from every specimen, each with 4-5 sections chosen 
carefully without folds, were selected for immunohistochemical 
staining. These were incubated in a 57°C oven overnight, the night prior 
to staining. While staining each set of slides, one slide known to contain 
CD1a positive LCs was also stained as positive control. Not more than 
10 slides were stained in each session. 
 
Polymer-horseradish peroxidase (HRP) detection system 
 A modification of standard avidin-biotin peroxidase technique 
known as polymer-HRP detection system was used in this study. This 
biotin free detection system was used to eliminate the problems of 
endogenous biotin. 
 
I. The Universal HRP Detection system ready-to-use kit was purchased 
from SCYTEK Laboratories, USA. This pack includes the following 
reagents: 
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1. Peroxide block: 3% hydrogen peroxide in water. This was used 
to reduce nonspecific background staining due to endogenous 
peroxidises. 
2. Super block reagent: 0.25% casein (hydrophilic protein) in 
Phosphate Buffered Saline (PBS) containing stabilizing protein 
and 0.015mol/L sodium azide. This is a unique serum-free 
protein blocking agent. 
3. Anti polyvalent HRP polymer: This utilizes a polymerized HRP 
label that eliminates biotin and its associated background 
issues from the equation. Effective with antibodies of mouse, 
rat, rabbit and guinea pig. 
4. Diaminobenzidine (DAB) chromogen concentrate in the 
presence of the peroxidase enzyme, DAB produces a brown 
precipitate that is insoluble in alcohol. 
5. DAB substrate: Tris buffer containing peroxides and 
stabilizers. 
II. The primary antibody used was the monoclonal mouse anti-human 
CD1a (DAKO, USA)  
 
Principle of the HRP detection system 
 The demonstration of CD1a antigen in tissues by 
immunohistochemistry method includes two steps 
 Step 1 – binding of antibody with antigen of interest in specific tissues. 
 Step 2 – by using various enzyme chromogenic systems the above 
bound antibody is visualized. 
42 
 
Solutions prepared: 
I. Two buffers were prepared namely 
1. EDTA buffer (pH 9.0) – used  during antigen retrieval stage 
2. TRIS buffered saline (pH 7.6) – used as wash buffer  
For staining 20 slides, the following quantity of buffer solutions were 
prepared 
1. EDTA buffer (1litre) 
a. Tri hydroxy methyl methylamine (Tris) – 6.05 grams 
b. Ethylene diamine tetra acetic acid (EDTA) – 0.7465grams 
c. Distilled water – 1 litre 
The above solutions were mixed well with a glass stir rod and the 
pH was adjusted to 9.0 
2. Tris buffered saline (TBS – 2 litres) 
a. Sodium chloride – 16 grams 
b. Tris – 1.210grams 
c. 1 normal hydrochloric acid – 8 ml 
d. Distilled water – 2 litres 
The above solutions were mixed well with a glass rod and the pH 
was adjusted to 7.6 
II. Preparation of Harri’s Haematoxylin 
 Distilled water – 200ml 
 Harri’s haematoxylin powder – 1 gram 
 Absolute isopropyl alcohol – 10ml 
 Potassium alum – 20g 
 Mercuric oxide – 0.5gram 
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 Powerful nuclear stain Harri’s haematoxylin powder was 
dissolved in absolute isopropyl alcohol by using pestle and mortar. In 
the florence flask, first the alum was dissolved in distilled water 
followed by adding the solutions of dissolved Harri’s Haematoxylin and 
mixed well. The flask was heated on a coil stove and then mercuric 
oxide was added slowly into it. Once the solution became dark purple it 
was off the heat and allowed to cool. The solution was filtered before 
each staining.  
Staining method: 
1. Selected slides were taken from 57°C incubator and then 
deparaffinised in xylene for 30 minutes.   
2. The slides were immersed in absolute isopropyl alcohol, for 2 
changes of 1 minute each to remove the xylene. 
3. Slides were washed for 10 minutes in running water to remove the 
alcohol. 
4. Antigen retrieval: The antigenic epitopes are masked by formalin 
cross links formed during the processes of fixation and embedding. 
Different primary antibodies have different techniques of antigen 
retrieval. The heat retrieval method was used for CD1a antigen 
retrieval in this study. Steps used were as follows: 
a. A trough with EDTA buffer was preheated by heating in a 
pressure cooker without weight until steam emerged.  
b. Meanwhile the slides were transferred from running water 
to distilled water for 1-2 minutes. They were then arranged 
adequately spaced, in a slide rack and transferred to the 
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preheated EDTA buffer. The cooker lid was closed, the cooker 
weight valve was applied and returned to the heat. 
c. After two whistled (approximately 10 minutes) the cooker 
was taken off, the stove and kept inside a sink filled with water 
for rapid cooling. The slides in which sections hadn’t floated 
were selected and transferred into distilled water for 5 
minutes. 
d. The slides were then washed in TBS twice, each time for 5 
minutes. 
The remaining steps were carried out in an air conditioned room 
5. The slides were arranged on a humidified chamber. 
6. Peroxidase blocking solution was applied over each section for 10                   
minutes to block endogenous Peroxidase. This was conducted in a 
dark room to avoid decomposition of the hydrogen peroxide in the 
solution. 
7. The excess solution was drained from each slide and slides were 
rearranged in the slide rack. The slides were dipped in 2 changes of 
distilled water and then placed in TBS for 15 minutes. 
8. Excess solutions was wiped from each slide around the tissue   
sections and then super block was applied over each tissue section 
and returned to the humidification chamber for 10 minutes, to 
block the endogenous proteins. 
9. Excess super block was drained and primary antibody was applied   
over each section using a micropipette and slides were placed inside 
the humidification chamber for 1 hour.  
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10. Excess primary antibody was drained and slides were washed in          
TBS, 2 changes each for 5 minutes. 
11. Enzyme labelled secondary antibody was applied over each 
section and kept inside the humidification chamber for 30 minutes. 
12. Excess antibody solution was drained and washed in TBS, 2 
changes, each for 5 minutes. 
13. Meanwhile DAB working solution was prepared freshly by adding 1 
drop of DAB chromogen to 1ml of DAB substrate and it was mixed 
well. 
14. DAB working solution was added to each section, in a dark room 
to prevent decomposition of hydrogen peroxide, and kept in the 
humidification chamber for 5-8 minutes. 
15. Excess DAB solution was drained; the slides were washed in TBS 
for 5 minutes and then placed under running water for 10 minutes. 
16. To stain the nuclei of each cell, all slides were counterstained by 2 
dips in freshly prepared Harri’s alum Haematoxylin. Excess stain 
was removed by washing in tap water.  
17. The slides were dipped in lithium carbonate solution for blueing 
effect and then kept under running water for five minutes. 
18. Finally slides were air dried, dipped in xylene and mounted with 
mixture of distyrene plasticizer and xylene (DPX). 
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4.6 ANALYSIS 
Qualitative analysis 
 
 The stained slides were examined under the light microscope 
Olympus BX43 and photos were taken by using Olympus DP21 camera 
fitted on light microscope. The presence and morphology of the 
epithelium was confirmed by studying the H & E stained slides. The 
test of the study was conducted in the slides stained with CD1a. The 
morphology of CD1a positive Langerhans cells present in the mucosa of 
the ectocervix was noted.  
 
Quantitative analysis 
 
 Cellsens standard image analyzing software (version 1.4) was 
used for the morphometric analysis. The number of CD1a positive LCs 
was counted and their diameters measured under 40x magnification 
using Cellsens analysing software. There were 5 groups of specimens 
collected namely, normal cervix, CIN I, squamous cell carcinoma, 
adenocarcinoma of cervix and normal cervix associated with other 
genital carcinomas. The number of CD1a positive LCs per 25mm length 
of ectocervical epithelium was counted for each specimen and the data 
classified into the five categories mentioned above. The length of 
epithelium was measured along the basement membrane using the 
image analysing software (Figure 2). Only the cells with well defined 
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nuclei were counted. LCs were categorized into six types, the five types 
as mentioned in the Figueroa and Caorsi classification (26) and an 
additional type of cells without processes. The average number of each 
type of LC and total number were calculated per mm length of 
epithelium. The diameters of the LCs were taken in two perpendicular 
axes (Figure 3). The diameters of hundred LCs per specimen with well 
defined nuclei were measured in micrometers. The average diameters of 
the cells were calculated. 
 
Statistical analysis 
 
  The data was analysed using SPSS version 16. The descriptive 
statistics (range, mean and standard deviation) were obtained. The 
difference in the total number of LCs and different types of CD1a 
positive LCs per mm length of ectocervical epithelium were compared 
between the five groups using the Kruskal-Wallis test and post hoc test 
between pairs of groups using the Mann-Whitney U test was done at 
1% level. The mean diameter of LCs were compared between the five 
groups by ANOVA and post hoc test between pairs of groups using the 
Scheffe multiple comparison test was done at 1% level. 
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5. RESULTS 
Morphology and distribution of CD1a positive LCs in 
normal and cancerous cervical tissues using 
immunohistochemistry. 
  
 The cervix specimens collected were categorized into five groups 
based on their histopathological diagnosis namely normal cervix, 
cervical intraepithelial neoplasia I (CIN I), squamous cell carcinoma of 
cervix, adenocarcinoma of cervix and normal cervix associated with 
other genital carcinomas such as carcinoma endometrium and 
carcinoma ovary.  
 
Normal cervix 
 Stratified squamous epithelium lining the ectocervix showed the 
presence of CD1a positive LCs in all the specimens. Regional variation 
was present in their distribution. The cells were randomly distributed in 
the epithelium. While some areas had relatively high density of LCs 
(Figure 4), some areas were devoid of LCs (Figure 5). These cells showed 
the classical morphology of dendritic cells. In the epithelium, CD1a 
positive LCs were present mainly in the suprabasal and midepithelial 
layers (Figure 4). Few LCs were also noted in the lamina propria of 
ectocervix (Figure 4).  The mean number of CD1a positive LCs per mm 
length of normal ectocervical epithelium was 8 ± 2.76. The diameter of 
the CD1a positive LCs ranged from 4.08 to 15.31m with a mean 
diameter of 8.57 ± 1.81m (Table 1).  
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 In the epithelium of the normal cervix, all five types of LCs as 
classified by Figueroa and Caorsi (16) were identified. In addition, CD1a 
positive cells without processes but having round nuclei were also 
present (Figures 6a & 6b). Chart 1 & Table 2 show the percentages of 
each type of LC present in the normal ectocervix. The number of type I 
LCs was significantly higher than other types of LCs except for the cells 
without processes (p < 0.001) (Table 3).  LCs migrating through the 
basement membrane were also observed (Figure 7).  
Table 1: The number of CD1a positive LCs per mm length of 
ectocervical epithelium and diameter of cells in the normal cervix 
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Chart 1: Percentage of different types of 
CD1a+ LCs in the normal cervix  
Normal cervix Mean 
Standard 
deviation 
Minimum Maximum 
Number 8.00 2.76 3.84 16.04 
Diameter (m) 8.57 1.81 4.08 15.31 
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Table 2: Distribution of different types of CD1a positive LCs per 
mm length of normal ectocervical epithelium and comparison of all 
the types of LCs using the Kruskal Wallis test. 
 
 
  p < 0.05 is significant 
 
  
 
 
 
Types of 
LCs 
 
Mean 
Standard 
deviation 
Minimum Maximum Percentage p value 
Type I 
 
2.65 0.99 1.32 4.68 33.17% 
 
 
 
 
 
 
<0.001 
Type II 
 
0.78 0.65 0.12 2.40 9.79% 
Type III 
 
1.85 0.98 0.48 4.56 23.06% 
Type IV 
 
0.64 0.45 0.16 1.80 8.04% 
Type V 
 
0.23 0.42 0.00 1.68 2.91% 
No 
processes 
 
1.84 1.01 0.12 3.76 23.02% 
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  Table 3: Comparison between types of LCs within the normal 
cervix using the Mann Whitney U test   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
       
      p < 0.01 is significant 
     
S.No 
Comparison  between types of 
LCs  in the normal cervix 
 
p value 
 
1. Type I vs. type II < 0.001 
2. Type I vs. type III 0.005 
3. Type I vs. type IV < 0.001 
4. Type I vs. type V < 0.001 
5. Type I vs. no processes 0.019 
6. Type II vs. type III < 0.001 
7. Type II vs. type IV 0.723 
8. Type II vs. type V < 0.001 
9. Type II vs. no processes < 0.001 
10. Type III vs. type IV < 0.001 
11. Type III vs. type V < 0.001 
12. Type III vs. no processes 0.785 
13. Type IV vs. type V < 0.001 
14. Type IV vs. no processes < 0.001 
15. Type V vs. no processes < 0.001 
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Cervical intraepithelial neoplasia I 
  The CD1a positive LCs were predominantly present in the 
suprabasal layer of the stratified squamous epithelium in the 
specimens with cervical intraepithelial neoplasia stage I.  The mean 
number of CD1a positive LCs per mm length of stratified squamous 
epithelium was 10.02 ± 2.01. The diameter of the CD1a positive 
Langerhans cells ranged from 5.38 to 13.31m with a mean diameter of 
8.75 ± 1.67m (Table 4). These cells had well defined nuclei and 
variable number of long processes (Figure 8). The cells with either single 
or no processes were predominant. There was 35.13% of type I cells and 
cells with no processes accounted for 33.93% of cells. Cells with three 
or more processes i.e. type IV and V were decreased in number.  There 
were only 3.99% of type IV and 0.8% of type V cells were present in CIN 
I ectocervix (Chart 2 and Table 5).  
Table 4: The number of CD1a positive LCS per mm length of 
ectocervical epithelium and diameter of cells in cervical 
intraepithelial neoplasia I  
 
CIN I Mean 
Standard 
deviation 
Minimum Maximum 
Number 10.02 2.01 8.6 11.4 
Diameter (m) 8.75 1.67 5.38 13.31 
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Table 5: Distribution of different types of CD1a positive LCs per 
mm length of ectocervical epithelium in CIN I and comparison of 
all the types of LCs using the Kruskal Wallis test. 
p value < 0.05 is significant 
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Chart 2: Percentage of different types of CD1a+ LCs 
in CIN I group 
Types of 
LCs 
Mean 
Standard 
deviation 
Minimum Maximum Percentage 
p 
value 
Type I 3.52 0.17 3.40 3.64 35.13% 
0.082 
Type II 1.26 1.33 0.32 2.20 12.57% 
Type III 1.36 0.51 1.00 1.72 13.00% 
Type IV 0.40 0.28 0.20 0.60 3.99% 
Type V 0.08 0.11 0.00 0.16 0.80% 
No 
processes 
3.40 1.41 2.40 4.40 33.93% 
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Squamous cell carcinoma of cervix 
 
 In the specimens with squamous cell carcinoma of the ectocervix, 
CD1a positive LCs were randomly distributed. They were seen either in 
the entire thickness (Figure 9), or in the suprabasal layer (Figure 10), or 
in the midepithelium (Figure 11), or infrequently in the superficial layer 
(Figure 12). The number of CD1a positive LCs was decreased in the 
epithelium of ectocervix in squamous cell carcinoma. Their mean 
number per mm length of ectocervical epithelium was 5.36 ± 2.88. The 
diameter of the CD1a positive Langerhans cells ranged from 3.50 to 
17.03m with a mean diameter of 8.28 ± 2.04m (Table 6). These were 
predominantly cells with single process or rounded cells without 
dendritic processes as described later (Chart 3 and Table 7). The 
number of type I cells and cells with no processes was significantly 
higher than type II, type IV and type V cells (p < 0.001) (Table 8). 
 
Table 6: The number of CD1a positive LCs per mm length of 
ectocervical epithelium and diameter of cells in squamous cell 
carcinoma of cervix 
 
Squamous cell 
carcinoma of cervix 
Mean 
Standard 
deviation 
Minimum Maximum 
Number 5.36 2.88 1.64 11.48 
Diameter (m) 8.28 2.04 3.50 17.03 
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Table 7: Distribution of different types of CD1a positive LCs per 
mm length of ectocervical epithelium in squamous cell carcinoma 
of cervix and comparison of all the types of LCs using the Kruskal 
Wallis test. 
 
Types of 
LCs 
Mean 
Standard 
deviation 
Minimum Maximum Percentage p value 
Type I 1.57 0.79 0.40 3.28 29.26% 
< 0.001 
Type II 0.32 0.30 0.00 0.88 6.04% 
Type III 1.15 0.94 0.04 3.08 21.52% 
Type IV 0.37 0.32 0.00 1.00 6.92% 
Type V 0.24 0.32 0.00 1.00 4.48% 
No 
processes 
1.70 0.78 1.00 3.12 31.77% 
 
p value < 0.01 is significant 
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Chart 3: : Percentage of different types of 
CD1a+ LCs in squamous cell carcinoma of cervix   
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Table 8: Comparison of the types of LCs within the squamous cell 
carcinoma of cervix using the Mann Whitney U test  
 
p value < 0.01 is significant 
S.No 
Comparison of the types of LCs  
in  squamous cell carcinoma of 
cervix 
 
p value 
 
1. Type I vs. type II < 0.001 
2. Type I vs. type III 0.176 
3. Type I vs. type IV < 0.001 
4. Type I vs. type V < 0.001 
5. Type I vs. no processes   0.987 
6. Type II vs. type III  0.008 
7. Type II vs. type IV 0.735 
8. Type II vs. type V 0.370 
9. Type II vs. no processes < 0.001 
10. Type III vs. type IV  0.015 
11. Type III vs. type V 0.001 
12. Type III vs. no processes 0.076 
13. Type IV vs. type V  0.184 
14. Type IV vs. no processes < 0.001 
15. Type V vs. no processes < 0.001 
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Moderately differentiated squamous cell carcinoma of 
cervix 
 
 Two moderately differentiated squamous cell carcinoma 
specimens with nodal metastasis had a large number of CD1a positive 
LCs. In the epithelium, all five types of LCs were noted and in addition, 
there were many cells without any cell processes. These cells were 
rounded, less intensely stained and lacked cytoplasmic processes 
(Figure 13).  In the region where lymphocytic infiltration was seen in the 
epithelium, large numbers of CD1a positive LCs were noted (Figure 14). 
The remaining specimens with moderately differentiated squamous cell 
carcinoma showed a low number of CD1a positive cells. The mean 
number of LCs per mm length of ectocervical epithelium was 6.82 ± 
3.76 (Table 9).   
 
Table 9: Mean number of CD1a positive LCs per mm length of 
ectocervical epithelium in poorly and moderately differentiated 
squamous cell carcinoma of cervix 
 
  
 
 
Squamous cell 
carcinoma of cervix 
 
Mean 
Standard 
deviation 
Minimum Maximum 
Moderately 
differentiated 
6.82 3.76 1.64 11.48 
Poorly differentiated 4.14 1.15 2.68 5.64 
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 In the lamina propria of moderately differentiated squamous cell 
carcinoma, a few CD1a positive cells were present. In cases with nodal 
involvement, there was a dense infiltration of LCs and lymphocytes in 
the underlying lamina propria (Figure 15).  Large numbers of LCs was 
seen in the lamina propria where there were lymphocytic aggregations 
(Figure 16). Migration of LCs across the basement membrane was 
observed. LCs were also seen in close association with blood vessels 
(Figure 17). 
 
Poorly differentiated Squamous cell carcinoma of cervix 
 
 Low numbers of CD1a positive LCs were noted in all cases of 
poorly differentiated squamous cell carcinoma (Figure 18). Although the 
number of cells per mm was relatively low, wherever there were 
infoldings of basement membrane, large numbers of LCs were noted 
(Figure 19). The mean number of LCs per mm length of ectocervical 
epithelium was 4.14 ± 1.15 (Table 9). 
 Though the number of CD1a positive LCs was sparse in the intact 
epithelium away from the tumour area, dense infiltrations of CD1a 
positive LCs was noted in the tumour area and its adjacent epithelium 
(Figure 20). A few LCs were present in the lamina propria (Figure 21). In 
addition, HEVs with lymphocytes in their lumina were seen in the 
lamina propria. Close apposition of LCs and the lymphocytes were 
demonstrated in the lumina of HEVs.  CD1a positive LCs were seen in 
close contact with the walls of HEVs (Figure 22).  
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Adenocarcinoma of cervix 
 
 The CD1a positive LCs were scattered through all the layers of 
the stratified squamous epithelium in adenocarcinoma of cervix. Their 
mean number per mm length of ectocervical epithelium was 3.63 ± 
2.09. The diameters of the CD1a positive Langerhans cells ranged from 
3.24 to 14.51m with a mean diameter of 7.56 ± 1.95m (Table 10). 
Moderately differentiated adenocarcinoma had type I and type III cells 
in addition to cells with no processes (Chart 4 and Table 11). There was 
one specimen of a well differentiated adenocarcinoma which had a few 
CD1a positive LCs in the epithelium, which were predominantly 
rounded without processes (Figure 23). Large numbers of LCs were 
noted in the regions of epithelium with lymphocytic infiltrations (Figure 
24).  A few LCs were found in the lamina propria. 
 
Table 10: The number of CD1a positive LCs per mm length of 
ectocervical epithelium and diameter of cells in the of 
adenocarcinoma of cervix 
  
  
Adenocarcinoma 
of cervix 
 
Mean 
Standard 
deviation 
Minimum Maximum 
Number 3.63 2.09 1.40 5.64 
Diameter (m) 7.56 1.95 3.24 14.51 
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Table 11: Distribution of different types of CD1a positive LCs per 
mm length of ectocervical epithelium in adenocarcinoma of cervix 
and comparison of all types of LCs using the Kruskal Wallis test. 
 
p < 0.05 is significant 
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Chart 4: Percentage of different types of 
CD1a+ LCs in adenocarcinoma of cervix 
Types of 
LCs 
 
Mean 
Standard 
deviation 
Minimum Maximum Percentage 
p 
value 
Type I 
 
1.03 0.64 0.52 1.96 28.37% 
0.043 
Type II 
 
0.25 0.31 0.00 0.64 6.89% 
Type III 
 
0.82 0.66 0.24 1.52 22.59% 
Type IV 
 
0.26 0.33 0.00 0.72 7.16% 
Type V 
 
0.19 0.33 0.00 0.68 5.23% 
No  
processes 
1.08 0.51 0.60 1.72 29.75% 
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Normal cervix associated with other genital 
carcinomas  
 
 The CD1a positive LCs were seen mainly in the basal and 
suprabasal layers of the ectocervical epithelium. Their mean number 
per mm length of ectocervical epithelium was 5.51 ± 0.99. The diameter 
of the CD1a positive LCs ranged from 3.92 to 13.23m with a mean 
diameter of 7.90 ± 1.69m (Table 12). Most of them were type I cells and 
cells with no processes (Chart 5 and Table 13). The number of type I 
cells and cells with no processes was significantly higher than type II, 
type IV and type V cells (p < 0.001) (Table 14). Presence of CD1a 
positive LCs in the lamina propria was observed in regions of 
lymphocytic infiltrations (Figure 24). A few LCs were seen around the 
capillary wall in the lamina propria. In this study, in a case of 
endometroid adenocarcinoma of endometrium, a little endocervical 
tissue was obtained along with the specimens of ectocervix. In this, 
CD1a positive LCs were demonstrated in association with the 
endocervical glands. These cells had typical dendritic morphology 
although a few cells without dendritic processes were noted (Figures 
25a & 25b).  
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Table 12: The number of CD1a positive LCs per mm length and 
diameter of cells in the ectocervical epithelium in the normal 
cervix associated with other genital carcinomas 
 
Normal cervix 
associated with 
other genital 
carcinomas 
 
Mean 
Standard 
deviation 
Minimum Maximum 
Number 5.51 0.99 1.32 4.68 
Diameter (m) 7.90 1.69 3.92 13.23 
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Chart 5: Percentage of different types of CD1a+ 
LCs in cervix associated with other genital 
carcinoma 
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Table 13: Distribution of different types of CD1a positive LCs per 
mm length of ectocervical epithelium in the normal cervix 
associated other genital carcinomas and comparison of all the 
types of LCs using the Kruskal Wallis test. 
 
 
p value < 0.05 is significant 
 
 
 
 
 
 
 
Types of 
cells 
 
Mean 
Standard 
deviation 
Minimum Maximum Percentage p value 
Type I 1.96 1.16 0.09 4.08 36.84% 
<0.001 
Type II 0.28 0.24 0.01 0.64 5.18% 
Type III 1.16 0.72 0.05 2.12 22.29% 
Type IV 0.40 0.41 0.01 1.04 7.15% 
Type V 0.09 0.08 0.00 0.24 2.00% 
No 
processes 
1.62 0.80 0.08 2.64 27.06% 
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Table 14: Comparison of the types of LCs within the normal cervix 
associated with other genital carcinomas using the Mann Whitney  
U test 
 
p value < 0.01 is significant 
S.No 
Comparison of the types of LCs in the 
normal cervix associated with other 
genital carcinomas 
p value 
1. Type I vs. type II  0.003 
2. Type I vs. type III 0.111 
3. Type I vs. type IV 0.005 
4. Type I vs. type V 0.001 
5. Type I vs. no processes   0.664 
6. Type II vs. type III  0.008 
7. Type II vs. type IV 0.821 
8. Type II vs. type V 0.097 
9. Type II vs. no processes 0.003 
10. Type III vs. type IV  0.038 
11. Type III vs. type V 0.003 
12. Type III vs. no processes 0.246 
13. Type IV vs. type V  0.060 
14. Type IV vs. no processes 0.005 
15. Type V vs. no processes 0.001 
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I. Comparison of the number of CD1a positive LCs per 
mm length of the ectocervical epithelium in the 
categorized five groups. 
 
 The mean number of LCs per mm length of ectocervical 
epithelium was highest in CIN I (10.02 ± 2.01) and lowest in 
adenocarcinoma of cervix (3.63 ± 2.09). Using the Kruskal Wallis test it 
was found out that difference in the number of CD1a positive LCs per 
mm length of ectocervical epithelium between the five categorized 
groups was statistically significant (p value = 0.004) (Table 15).  
 
 The comparison between pairs of groups was done using the 
Mann Whitney U test. As evident in Table 16, the mean number of LCs 
was higher in the normal cervix (8 ± 2.76) compared to that of 
squamous cell carcinoma of cervix (5.36 ± 2.88). There was a 
statistically significant difference in the number of LCs between these 
two groups (p value = 0.006). Similarly, the mean number of LCs was 
higher in the normal cervix (8 ± 2.76) compared to that of 
adenocarcinoma of cervix (3.63 ± 2.09). This difference was also 
statistically significant difference in the number of LCs between the 
normal cervix and adenocarcinoma of cervix (p value = 0.003). 
 
 
 
 
 
 
79 
 
 
 
 
Table 15: Comparison of the number of CD1a positive LCs per mm 
length of the ectocervical epithelium between the five groups using 
the Kruskal Wallis test 
 
 
p < 0.05 is significant 
 
 
 
 
 
 
Groups 
 
Number of CD1a positive LCs  
 
    
  p 
value 
 
 Mean 
 
Standard 
deviation 
 
Minimum Maximum 
 
 
 
 
 
 
 
 
0.004 
Normal cervix 
 
 
8.00 2.76 3.84 16.04 
CIN I 
 
 
10.02 2.01 8.6 11.44 
Squamous cell 
carcinoma of cervix 
 
 
5.36 2.88 1.64 11.48 
Adenocarcinoma of 
cervix 
 
 
3.63 2.09 1.4 5.64 
Normal cervix 
associated with 
other genital  
carcinomas 
 
 
5.51 2.93 0.25 10.12 
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Table 16: Comparison of the number of CD1a positive LCs per mm 
length of the ectocervical epithelium between pairs of five groups 
using the Mann Whitney U test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
  
        p < 0.01 is significant  
 
S.No 
Comparison between pairs of groups 
 
P value 
1. 
Normal vs. CIN I 
 
0.214 
2. 
Normal vs. squamous cell carcinoma of cervix 
 
0.006 
3. 
Normal vs. adenocarcinoma of cervix 
 
0.003 
4. 
Normal vs. normal cervix associated with other 
genital carcinomas 
 
0.058 
5. 
CIN I vs. squamous cell carcinoma of cervix 
 
0.154 
6. 
CIN I vs. adenocarcinoma of cervix 
 
0.133 
7. 
CIN I vs. normal cervix associated with other 
genital carcinomas 
 
0.089 
8. 
Squamous cell carcinoma of cervix vs. 
adenocarcinoma of cervix 
 
0.263 
9. 
Squamous cell carcinoma of cervix vs. normal 
cervix associated with other genital carcinomas 
 
0.657 
10. 
Adenocarcinoma of cervix vs. normal cervix 
associated with other genital carcinomas 
 
0.368 
11. 
Moderately and poorly differentiated squamous 
cell carcinoma of cervix 
0.126 
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II. Comparison of the numbers of different types of CD1a 
positive LCs per mm length of the ectocervical 
epithelium in the five categorized groups. 
 
 The number of each type of LC per mm length of ectocervical 
epithelium was compared across the five categorized groups by using 
the Kruskal Wallis test. There was a statistically significant difference in 
the number of type I cells among the categorized five groups (p value = 
0.002) (Table 17). Similarly, there was a statistically significant 
difference in the number of type II cells among the categorized five 
groups (p value = 0.043) (Table 18). However, the difference in the 
number of other types of LCs namely type III (p= 0.095), type IV (p= 
0.147), type V (p=0.987) and no processes cells (p= 0.176) were not 
statistically significant when compared among the five categorized 
groups. 
 The p value obtained by comparing type I and II LCs between 
pairs of groups using Mann-Whitney U test at 1% level is shown in 
table 19. The mean number of type I LCs were higher in the normal 
cervix 2.65 ± 0.99 compared to that of squamous cell carcinoma of 
cervix 1.57 ± 0.79. There was a statistically significant difference 
between these two groups (p = 0.002). Similarly, the mean number of 
type I LCs were higher in the normal cervix 2.65 ± 0.99 compared to 
that of adenocarcinoma of cervix 1.03 ± 0.64. This difference was also 
statistically significant (p = 0.003) (Table 19). 
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Table 17: Comparison of the type I CD1a positive LCs per mm 
length of the ectocervical epithelium in the five groups using the 
Kruskal Wallis test 
 
 
 
p < 0.05 is significant 
 
 
 
 
Groups 
 
Number of type I CD1a positive LCs 
 
p 
value 
 
 
Mean 
 
Standard 
deviation 
 
 
 
Minimum 
 
Maximum 
0.002 
Normal cervix 
 
 
2.65 0.99 1.32 4.68 
CIN I 
 
 
3.52 0.17 3.40 3.64 
Squamous cell 
carcinoma of cervix 
 
 
1.57 0.79 0.40 3.28 
Adenocarcinoma of 
cervix 
 
 
1.03 0.64 0.52 1.96 
Normal cervix 
associated with  
other genital  
carcinomas 
 
 
1.96 1.16 0.09 4.08 
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Table 18: Comparison of the type II CD1a positive LCs per mm 
length of the ectocervical epithelium in the five groups using the 
Kruskal Wallis test 
 
 
p < 0.05 is significant 
 
 Although the difference between the number of type II LCs in the 
five groups was statistically significant (p= 0.043), the difference was 
not statistically significant between any two groups at 1% level (Tables 
18 & 19). 
Groups 
 
Number of type II CD1a positive LCs 
 
 
p 
value 
 
 
 
Mean 
 
Standard 
deviation 
 
 
Minimum 
 
Maximum 
 
 
 
 
 
 
 
 
 
 
0.043 
Normal cervix 
 
 
0.78 0.65 0.12 2.40 
CIN I 
 
 
1.26 1.33 0.32 2.20 
Squamous cell  
carcinoma of cervix 
 
 
0.32 0.30 0.00 0.88 
Adenocarcinoma of  
Cervix 
 
 
0.25 0.31 0.00 0.64 
Normal cervix 
associated with 
other genital  
carcinomas 
  
0.28 0.24 0.01 0.64 
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Table 19: Comparison of type I & II CD1a positive LCs per mm 
length of the ectocervical epithelium between pairs of groups using 
the Mann Whitney U test 
 
 
p < 0.01 is significant 
S.No 
Comparison between pairs of 
groups 
Type I 
LCs 
p value 
Type II 
LCs 
p value 
1. 
Normal cervix vs. CIN I 
0.138 0.634 
2. 
Normal cervix vs. squamous cell 
carcinoma of cervix 0.002 0.021 
3. 
Normal cervix vs. adenocarcinoma of 
cervix 0.003 0.077 
4. 
Normal cervix vs. normal cervix 
associated with other genital 
carcinomas 
0.138 0.023 
5. 
CIN I vs. squamous cell carcinoma 
of cervix 
0.026 0.282 
6. CIN I vs. adenocarcinoma of cervix 0.133 0.467 
7. 
CIN I vs. normal cervix associated 
with other genital carcinomas  
0.178 0.311 
8. 
 Squamous cell carcinoma of cervix 
vs. adenocarcinoma of cervix 
0.188 0.555 
9. 
Squamous cell carcinoma of cervix 
vs. normal cervix associated with 
other genital carcinomas 
0.319 0.855 
10. 
Adenocarcinoma of cervix vs. normal 
cervix associated with other genital 
carcinomas 
0.166 0.655 
11. 
Moderately vs. poorly differentiated 
squamous cell carcinoma of cervix 
 
0.160 0.946 
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III. Comparison of mean diameters of CD1a positive LCs 
in the five categorized groups 
 
 The diameter of hundred CD1a positive LCs was measured per 
sample. The average diameter of each LC with well defined nucleus was 
obtained by measuring the maximum diameter and minimum 
diameters. The range of diameters varied from 3.24 to 17.03m. The 
thickness of each section studied was 5m as it was believed, that the 
nucleus of a particular cell can be seen only in one section but not in 
the subsequent section. 
 
 The mean diameter of LCs was highest in CIN I (8.75 ± 1.67m) 
and lowest in adenocarcinoma of cervix (7.56 ± 1.95m). The difference 
in the mean diameters of LCs among the five groups was analysed by 
ANOVA test. It was found that the mean difference in the diameters of 
LCs was statistically significant (p value < 0.001) in all five categorized 
groups (Table 20).  
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Table 20: Comparison of the mean diameters of CD1a positive LCs 
between the five groups by ANOVA test  
  
 
p value < 0.05 is significant 
 
 
 
Groups 
Mean LC 
diameter 
(m) 
 
Standard 
deviation 
Minimum Maximum p value 
Normal  cervix 
 
8.57 1.81 4.08 15.31 
 
 
 
 
 
 
 
<0.001 
 
CIN-I 8.75 1.67 5.38 13.31 
Squamous cell 
carcinoma of 
cervix 
 
8.28 2.04 3.50 17.03 
Adenocarcinom
a of cervix 
 
 
7.56 1.95 3.24 14.51 
Normal cervix 
associated with 
other genital 
carcinomas 
 
 
7.90 1.69 3.92 13.23 
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 The difference in the mean diameters between pairs of groups 
was done by   Scheffe multiple comparison test. As evident in the table 
21, the difference in the mean diameters of LCs was statistically 
significant between the following groups: 
The mean diameters of LCs in the  
 1. normal cervix (8.57 ± 1.81) was larger than that of squamous 
     cell carcinoma of cervix (8.28 ± 2.04) (p = 0.005). 
  
 2. normal cervix (8.57 ± 1.81) was larger than that of      
     adenocarcinoma of cervix (7.56 ± 1.95) (p value < 0.001). 
 
 3. normal cervix (8.57 ± 1.81) was larger than that of normal cervix 
    associated with other genital carcinomas (7.90 ± 1.69) (p value <  
     0.001). 
 
 4. CIN I (8.75 ± 1.67) was larger than that of adenocarcinoma of 
     cervix (7.56 ± 1.95) (p value < 0.001). 
 
 5. CIN I (8.75±1.67) was larger than that of normal cervix  
     associated with other genital carcinomas (7.90±1.69) (p value < 
     0 .001). 
 
 6. squamous cell carcinoma of cervix (8.28 ± 2.04) was larger 
     than that of adenocarcinoma of cervix (7.56 ± 1.95) (p value 
     <0.001). 
 
 7. squamous cell carcinoma of cervix (8.28 ± 2.04) was larger 
      than normal cervix associated with other genital carcinoma 
      (7.90 ± 1.69) (p = 0.002). 
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Table 21: Comparison of the mean diameters of CD1a positive LCs 
between pairs of groups using the Scheffe multiple comparison test 
S.No 
Comparison between pairs 
of groups 
 
95% confidence 
interval 
p 
value 
  
Lower 
bound 
Upper 
bound 
 
1. 
Normal cervix vs. CIN I 
-0.779 0.420 0.932 
2. 
Normal cervix vs. squamous 
cell carcinoma of cervix 0.059 0.532 0.005 
3. 
Normal cervix vs. 
adenocarcinoma of cervix 0.685 1.346 <0.001 
4. 
Normal cervix vs. normal 
cervix with other genital 
carcinomas 
0.401 0.942 <0.001 
5. 
CIN I vs. squamous cell 
carcinoma of cervix 
-0.128 1.078 0.208 
6. 
CIN I vs. adenocarcinoma of 
cervix 
0.549 1.841 <0.001 
7. 
CIN I vs. normal cervix with 
other genital carcinomas 
0.233 1.468 0.001 
8. 
 Squamous cell carcinoma of 
cervix vs. adenocarcinoma of 
cervix 
0.383 1.057 <0.001 
9. 
Squamous cell carcinoma of 
cervix vs. normal cervix 
associated with other genital 
carcinomas 
0.096 0.655 0.002 
10. 
Adenocarcinoma of cervix 
vs. normal cervix associated 
with other genital 
carcinomas 
-0.018 0.706 0.072 
 
p value < 0.01 is significant 
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6. DISCUSSION 
 Langerhans cells, a type of dendritic cells present in the mucosal 
layer, are said to be imperative in the recognition and processing of 
exogenous antigens as a part of immunomonitoring (14). They play an 
important role in protecting the host by acting as adjuvants and 
conductors of the immune response against infectious agents and 
neoplastic changes (55).   
   Langerhans cells have been demonstrated using various 
markers like ZIO (26,83,107), ATPase, MHC class II, S100 (108), HLA-
DR (15), vimentin (109) and CD1a. In this study to identify the LCs in 
the cervix, CD1a, a specific and sensitive immuno marker was used 
(64,65). CD1a is superior to other immune markers which recognize a 
number of other lymphoreticular cells such as macrophages or 
melanocytes.  Since the only other cell labelled by anti-CD1a antibodies 
is the immature thymocyte, CD1a is considered as the most specific 
marker for LCs (13). 
 Many studies have demonstrated the presence of LCs in normal 
and pathological cervical tissue (78–80,83,84). Studies have been 
conducted on LCs in the normal and cancer cervix using various 
markers like T6, ATPase, MHC class II and S100  and concluded that 
there are different subpopulations of LCs in cervix (108). Based on the 
surface markers, different subpopulations of LCs have been reported in 
other tissues like eyelid (110) and uterine tube (111). Different 
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subpopulations of LCs reflect functional differences among them (12). 
In ovarian carcinoma, it was found out that HLA-DR and CD1a positive 
LCs are more in patients without recurrence when compared to the 
groups with recurrence group. However S-100 positive LCs are more in 
the recurrence groups indicating the prognostic value of different 
subpopulations of LCs in tumours (112). The CD1a positive 
subpopulation of LCs is functionally distinct and is more important in 
antitumor immunity than the other subpopulations studied. This is 
because the CD1a surface antigen is a glycopeptide antigen presenting 
molecule and is a target in mixed lymphocyte reactions. The ability of 
LCs to stimulate mixed lymphocyte reactions and to activate T cells in 
vitro has been blocked by the antibody to CD1a (12).  
 The morphology and distribution of CD1a positive LCs in the 
normal and cancerous cervical tissues were considered by 
immunohistochemistry in this study. In accordance with earlier re[ports 
(16), in the present study there was regional variation in the 
distribution of CD1a positive LCs in the epithelium both in the normal 
and carcinoma specimens. While some areas had a high density of 
CD1a positive LCs others had no LCs at all.  
Position of LCs in the epithelium 
 Many previous studies have demonstrated LCs mainly in the 
basal and suprabasal layers of the stratified squamous epithelium of 
the normal cervix and vagina (15,75,111), and some in the midzone 
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(21). One report demonstrated LCs at all levels of the ectocervical 
epithelium, although preferentially in the intermediate and superficial 
layers (16). In other tissues which are lined by stratified squamous 
epithelium like normal oral mucosa, LCs were confined mainly in the 
suprabasal region. It was also noted in oral squamous cell carcinoma, 
LCs were distributed more towards the surface (8).    In the present 
study, the CD1a positive LCs were present in the suprabasal and 
intermediate layers of the stratified squamous epithelium lining the 
normal ectocervix. It was earlier reported that LCs were distributed 
throughout the entire thickness of stratified squamous epithelium in 
CIN except for the Grade I (114). In this study LCs were observed in the 
suprabasal layers of the ectocervical epithelium in CIN I. However, in 
the squamous cell carcinoma and adenocarcinoma of the cervix, the 
cells were distributed in all the layers.  
 
Number of LCs 
 There have been contradictory findings regarding the number of 
LCs in CIN and in cancer cervix. This could be due to the use of 
different markers representing different subpopulations of LCs in 
various studies. The distribution of different subpopulation of LCs may 
vary in normal, CIN and carcinoma.  
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Number of LCs in CIN  
 Our study demonstrated few LCs in case of dysplasia (82). Others 
reported a decrease in the number of epithelial CD1a positive LCs in all 
grades of CIN except CIN I, while using other markers like HLA-DR, 
HLA-DQ showed increased number of LCs (114). There is also a report 
of low numbers of LCs in CIN I lesions (79). And another showing low 
levels of LCs in association with CIN II and III lesions (115). OKT-6 
positive LCs (80), T6 positive LCs (108), S-100 positive LCs 
(108,116,117) and MHC II positive LCs (108,118) were significantly 
decreased in CIN and HPV infected cervix. Increased number of LCs in 
CIN when compared with normal also have been reported by different 
authors by using various markers including S-100, gold chloride and 
CD1a (14,119–122). In the present study, the mean number of CD1a 
positive LCs was highest in CIN I when compared with normal and 
carcinoma cervix.  The increased number of LCs in CIN I could be due 
to host immune response. LCs have been recognised as powerful 
antigen presenting cells capable of engulfing antigens either by 
phagocytosis, pinocytosis and endocytosis. They then efficiently present 
the processed antigens to lymphocytes, inducing a primary immune 
response.  
Number of LCs in carcinoma cervix 
 Using S-100 and OKT6 high density of LCs have been 
demonstrated among the cells exfoliated from the squamous cell 
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carcinomas of ectocervix (123). Increased number of LCs in invasive 
carcinomas have also been noted (54,120,124). The aberrant expression 
of HLA-DR positive LCs in CIN which is maintained even after the 
progression of CIN into carcinoma cervix has been demonstrated (125). 
However other studies have demonstrated reduction in the number of 
LCs in carcinoma cervix (21,84,126). Reduction in the number of LCs 
has been reported in other conditions like HPV 16 infection of the 
epidermis (127), oral squamous cell carcinoma (8) and breast 
carcinoma (98). In the present study, LCs were more in number in the 
normal and CIN I whereas squamous cell carcinoma of cervix, 
adenocarcinoma of cervix and normal cervix associated with other 
genital carcinomas showed fewer LCs in the epithelium of ectocervix. 
This is in accordance with authors who reported increased number of 
LCs in CIN and decreased number of LCs in squamous cell carcinoma 
of cervix (84). In this present study, the number of CD1a positive LCs 
was significantly lower in squamous cell carcinoma of the cervix as 
compared to normal cervix.  Similar findings have been reported in the 
past (126).   
 The decreased number of LCs in the ectocervical epithelium in 
carcinoma cervix is due to a suppressed host immune response. 
Tumours avoid immunosurveillance through various mechanisms 
including inhibition of recruitment of host DCs and local production of 
immunosuppressive factors (128). The low number of LCs is responsible 
for escape of tumour cells from immune recognition and elimination. 
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Many tumour derived factors including cytokines and inflammatory 
mediators alter the immune status of an individual especially by 
targeting LCs differentiation, maturation and also affect lifespan by 
forming apoptotic DCs and their precursors (129).   
LCs in tumour area 
 In the present study, ectocervical specimens were collected away 
from the tumour area but two specimens showed areas infiltrated by 
tumour. It was noted that although the number of CD1a positive LCs 
was sparse in the intact epithelium away from the tumour area, there 
was infiltration of CD1a positive LCs in the tumour area. This could be 
due to the migration of LCs towards the tumour area. It has been 
reported earlier that cytokines like IL-10 and VEGF produced by the 
tumour cells inhibit the maturation of LCs. The immature LCs present 
in and around the tumour lack the co-stimulatory molecules which are 
necessary for presenting tumour cell membrane information to the T 
lymphocytes. This results in ineffective immune response and disease 
progression (25). On the other hand, several studies have found 
correlation between the presence and number of LCs within the tumour 
tissues and clinical prognosis. The tumours infiltrated with large 
numbers of LCs were associated with better prognosis, longer patient 
survival and reduced recurrence (130). Higher LCs infiltration in 
tumour and peritumoral areas was reported to be associated with better 
prognosis in adenocarcinoma of cervix (131), oesophageal squamous 
cell carcinomas (93), ovarian cancers (112), tongue squamous cell 
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carcinomas  (12), glottic squamous cell carcinomas (10), gastric 
carcinomas (68) and thyroid carcinomas (132). However, lack of this 
correlation in laryngeal squamous cell carcinomas indicates cancer 
survival is multifactorial as opposed to a single factor like LCs 
determining the prognosis (13).  
LCs in lymphocyte infiltration 
 In the present study, large numbers of CD1a positive LCs were 
noted in regions of lymphocytic infiltration either in the epithelium or 
lamina propria.  This is in accordance with a earlier study 
demonstrating lymphocytic infiltration with large numbers of LCs both 
in epithelium and lamina propria of the normal ectocervix (77). 
Similarly, there was a report of increased number of LCs with evident 
infiltration of lymphocytes, mainly cytotoxic T cells in patients with 
laryngeal squamous cell carcinomas (13). While one report showed the 
presence of S-100 positive LCs  predominantly around the lymphocytic 
aggregates and capillaries in CIN (108), Others demonstrated very few 
CD1a positive LCs in the lymphoid infiltrates of ductal carcinoma of the 
breast (97). A study investigating HLA-DR positive LCs and T 
lymphocytes in and around the tumour nests of squamous cell 
carcinoma of the oesophagus concluded dense infiltration of LCs and 
lymphocytes was associated with better prognosis (93).  
 In addition to the LCs, intraepithelial lymphocytes have been 
demonstrated in the ectocervical epithelium. In the normal cervix both 
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CD4 and CD8 subset were demonstrated (133). Recognition by helper 
lymphocytes of the antigens presented by LCs are important for 
triggering the immune response (33). However, in cancer cervix, the 
intraepithelial lymphocytes are predominantly of cytotoxic type (134). 
Cytotoxic T lymphocyte may control the penetration of antigens by 
killing epithelial cells bearing exogenous molecules on their surface. 
Contact between LCs and intraepithelial lymphocytes have been 
demonstrated (83). The LC-T cell interaction is crucial for T cell 
activation and differentiation in the neoplastic process (81). 
Types of LCs 
 The different types of CD1a positive LCs found in the human 
ectocervix represent different degrees of antigenic stimulation of the 
cells. Those with the largest number of processes have more surface 
receptors and display a high antigen-binding activity (16). Figueroa and 
Caorsi reported type I and type III cells were the most numerous 
whereas those of Type V were the least frequent in the normal 
ectocervical epithelium. The present study also showed the cells with 
single and two processes were more predominant in the normals, those 
with CIN and carcinoma cervix. Although cells with more processes 
were scanty, they were relatively more in the adenocarcinoma and 
squamous cell carcinoma of cervix when compared with normal cervix 
and CIN I. This is in accordance with the study reporting that most 
ramified types of LCs were more abundant in the neoplastic exocervix 
(83). Another study reported that in neoplasia, S-100 positive LCs was 
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most abundant. The branched type indicates hyperactivity. This 
hyperactivity may help to overcome the tumour progression (122). In 
the present study, loss of dendritic processes was demonstrated 
morphologically by immunostaining with CD1a in CIN I and carcinoma. 
Cells with no processes were relatively high in CIN I and carcinoma. 
Loss of dendritic process has also been reported in viral wart infection 
of cervix (135). The loss of dendritic processes may indicate that 
immune function of LCs is defective in patients with CIN and cancer. 
Although the LCs have anti-tumour activity in normal condition, in 
cancerous lesion they are malfunctioned and polarized into 
immunosuppressive LCs resulting in tumour progression (87). 
Diameters of CD1a positive LCs 
 It was found in the present study that the mean diameters of 
CD1a positive LCs were larger in the normal cervix and CIN I when 
compared with  both squamous cell and adenocarcinomas of the cervix, 
which could mean LCs in normal and CIN I may be more metabolically 
active. In cervical carcinoma, cell organelles may be sparse, 
contributing to the smaller size of the LCs.   
Migration of LCs 
 In the present study migration of LCs across the basement 
membrane was observed. GM-CSF plays an important role in migration 
of LCs. The keratinocytes of the normal cervix induces LC migration by 
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increased production of GM-CSF but HPV transformed keratinocytes 
have less capacity to produce the above factor thereby inhibiting the 
migration of LCs (136). Prevention of LC migration may be a mechanism 
used by both viruses and tumours to evade activation of host immune 
responses (137). TNF-α provides an important signal for LC migration 
and that in the absence of this cytokine, movement of LC from the 
epidermis to regional lymph nodes is inhibited. Recent evidence 
indicates that interleukin-1 beta, a cytokine produced in murine 
epidermis exclusively by LC, may play a role in LC migration across the 
basement membrane (138).  
LCs in endocervical glands 
 In this study, CD1a positive LCs were seen in the endocervical 
glands of endometroid adenocarcinoma of the endometrium which had 
typical dendritic morphology, although a few cells were noted with loss 
of dendritic processes Small numbers of vimentin and T6 positive LCs 
have been demonstrated in the endocervical epithelium of the normal 
cervix (82). Previous studies have demonstrated other subpopulation of 
LCs like ZIO positive LCs in the endocervix which were of columnar 
shape. It was reported that ZIO positive LCs increase in endocervicitis 
(107). The presence of CD1a positive LCs in the endocervix may indicate 
the role of this subpopulation of LCs in the local immune response. 
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High endothelial venules 
 In this study HEVs, specialized post capillary venules lined by 
cuboidal endothelial cells, were noted in the lamina propria of the 
ectocervix in squamous cell carcinoma. The migration of naïve T and B 
lymphocytes through  HEVs is limited by the LCs surrounding it (105). 
Previous studies have demonstrated vessels similar to HEVs in the 
stroma of various carcinomas. The tumour induced HEVs were 
associated with increased levels of B and T lymphocyte infiltration and 
good prognosis in breast carcinoma, with inhibition of the tumour 
metastasis (139). Although the formation of blood vessels and 
angiogenesis in the tumour area were related to poor prognosis, high 
levels of HEVs were associated with good prognosis by enhancing the 
numbers of memory and cytotoxic T lymphocytes infiltrating along with 
inhibition of the tumour metastasis (139). Chronic inflammatory 
diseases and cancers can be prevented by enhancing factors involved in 
maintenance of HEVs (104). The close association of LCs with 
capillaries and HEV demonstrated in the present study suggests the 
possible role of LCs in immunosurveillance and the presentation of 
antigens to lymphocytes.  
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 The sample size determined was 35 each in the normal cervix and 
squamous cell carcinoma groups. The specimens collected were 22 of 
normal cervix, and 8 of normal cervix associated with other genital 
carcinoma. However, only 11 samples were obtained from squamous 
cell carcinoma of cervix and 4 of adenocarcinoma of cervix. From the 
data obtained from the collected sample sizes, it was found that there 
was statistically significant difference in the number of LCs between 
normal and squamous cell carcinoma and also between normal and 
adenocarcinoma of cervix and in retrospect this sample size was found 
adequate to be representative. 
 In summary, in this study the distribution and morphology of 
CD1a positive LCs were studied in normal, CIN I, carcinoma of cervix 
and normal cervix associated with other genital carcinomas. Cancer of 
the cervix is unique among other cancers because of its preventable 
nature by screening and removal of precancerous lesions. Dendritic 
cell-based vaccines have been developed to treat cervical dysplasia and 
HPV related diseases (140). High accessibility of preventive programs 
like screening and vaccination is mandatory to overcome carcinoma 
cervix. The data provided in this study may shed new insights to 
understand the role of CD1a positive LCs in carcinoma cervix. 
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7. CONCLUSIONS 
1. All the cervical specimens showed the presence of CD1a positive 
LCs. 
2. Regional variation was noted in the distribution of LCs. 
3. In the normal ectocervix, LCs were predominantly present in the 
suprabasal and intermediate layers of stratified squamous 
epithelium. 
4. In CIN I LCs were predominantly present in the suprabasal layer 
of the ectocervical epithelium. 
5. In case of carcinoma of cervix, LCs were seen either in the entire 
thickness, in the suprabasal or mid-epithelial layers, or 
infrequently, in the superficial layers of the ectocervical 
epithelium. 
6. In addition to the five types of LCs classified by Figueroa and 
Caorsi (26), LCs with no processes were also noted in all the 
specimens. 
7. While in the normal cervix, CIN I and normal cervix associated 
with other genital carcinoma LCs predominantly had a single 
process (Type I), cells with no processes were predominant in the 
squamous cell carcinoma and adenocarcinoma groups. 
8. LC migration through the basement membrane was noted in all 
the five categorized groups. 
9. A large number of LCs was noted associated with lymphocytic 
infiltrations in both epithelium and lamina propria. 
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10. LCs were found in close association with the capillaries and HEVs 
in the lamina propria of cases with squamous cell carcinoma of 
the cervix. 
11. The mean number of CD1a positive LCs per mm length of 
ectocervical epithelium was highest in CIN I and in normal cervix 
when compared with carcinoma of cervix and normal cervix 
associated with other genital carcinomas. 
12. The number of CD1a positive LCs was significantly lower in 
squamous cell and adenocarcinoma of cervix as compared to 
normal cervix.   
13. The number of type I CD1a positive LCs was significantly higher 
in normal cervix as compared to squamous cell carcinoma of 
cervix.  
14. The number of type I CD1a positive LCs was significantly higher 
in normal cervix as compared to adenocarcinoma of cervix. 
15. Although the number of LCs was sparse in the intact epithelium 
away from tumour areas, dense infiltrations of LCs were noted in 
the tumour areas in poorly differentiated squamous cell 
carcinoma of cervix. 
16. The diameters of CD1a positive LCs were significantly higher in 
normal cervix as compared to squamous cell and adenocarcinoma 
of cervix and normal cervix associated with other genital 
carcinomas. 
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17. The diameters of CD1a positive LCs were significantly greater in 
CIN I as compared to adenocarcinoma of cervix and normal cervix 
associated with other genital carcinomas. 
18. The diameters of CD1a positive LCs were significantly higher in 
squamous cell carcinoma of cervix as compared to 
adenocarcinoma of cervix and normal cervix associated with other 
genital carcinomas. 
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8. FUTURE SCOPE OF THIS STUDY 
 
1. The distribution and morphology of CD1a positive LCs in CIN of 
different grades should be studied on more number of samples. 
2. Follow up studies of patients with carcinoma cervix included in 
this study can be done to see the relationship between the number 
of LCs and prognosis.  
3. Number of CD1a positive LCs in different tumour stages of 
squamous cell carcinoma of cervix with or without lymph node 
involvement can be studied.  
4. Different subpopulation of LCs in carcinoma cervix can be studied 
using various markers like S-100 and ZIO. 
5. Number of LCs in the peritumoural and tumoural areas can be 
estimated. 
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Christian Medical College, Vellore.  
Department of Anatomy 
An observational study on morphometrical analysis of antigen 
presenting CD1a positive Langerhans cells in human cervical 
tissues by immunohistochemistry method. 
   Patient Information sheet 
 You are kindly requested to participate in this study. As a part of 
this study after your surgery under Obstetrics and Gynaecology 
department, a bit of cervical tissue from the removed specimen will be 
collected. Your hospital chart will be referred for information regarding 
history, clinical examination and the biopsy report that has been done 
on you. This information will be utilized to analyze the association 
between the disease condition and the number of CD1a positive 
langerhans cells. Participation in this study will not change the quality 
of the treatment provided by the consulting doctors.  
 There is no potential harm or complication that can happen to 
you by participating in this study. All details including personal data 
will be kept highly confidential. 
 We hope to include about 60 people from this hospital in this 
study in the next 2 years. Participation in this study is purely 
voluntary, and that refusal to participate will not involve any penalty or 
loss of benefits to which you are otherwise entitled. 
In case of doubts/ questions, please contact: 
1. Dr. E. Mohana Priya, 
 Department of Anatomy,  
Christian Medical College,  
Vellore- 632002. Mobile no: 9865341757 
 
2. Dr. Anitha E Dorairaj,  
Department of Obstetrics and Gynaecology, Unit 1,  
Christian Medical College,  
Vellore- 632004. 
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Christian Medical College, Vellore. 
Department of Anatomy 
An observational study on morphometrical analysis of antigen 
presenting CD1a positive Langerhans cells in human cervical 
tissues by immunohistochemistry method 
Informed consent form 
(i) I confirm that I have read and understood the information sheet for 
the above study and have had the opportunity to ask questions.  
(ii) I understand that my participation in the study is voluntary and 
that I am free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected. 
 (iii) I understand and agree that the Sponsor of this study, others 
working on the Sponsor’s behalf, the Ethics Committee and the 
regulatory authorities will not need my permission to look at my 
hospital records both in respect of this study and any further research 
that may be conducted in relation to it, even if I withdraw from the 
same. However, I understand that my identity will not be revealed in 
any information released to third parties or when published. 
To this, I agree to take part in the above study.    
1. Signature (or Thumb impression) of the patient: 
Date: 
Patient’s Name: 
 
2. Signature of the witness:  
Date: 
Name of the witness:  
              
3. Signature of the Investigator 
Date: 
Study investigator’s Name: 
Study ID No: 
Hospital No:  
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    ABBREVIATIONS 
DCs  Dendritic cells 
MHC  Major histocompatibility complex 
LCs  Langerhans cells 
HPV  Human papilloma virus 
IL-10  Interleukin – 10 
VEGF  Vascular endothelial growth factor 
CD  Cluster differentiation 
TGF- β1 Transforming growth factor beta 1 
CIN  Cervical intraepithelial neoplasia 
SCC  Squamous cell carcinoma 
MDCs Myeloid dendritic cells 
PDCs  Plasmacytoid dendritic cells 
GM-CSF Granulocyte macrophage colony stimulating factor 
INF- α  Interferon alpha 
HLA-DR Human leukocyte antigen 
TRAIL Tumour necrosis factor related apoptosis inducing ligand 
OED  Oral epithelial dysplasia 
HEVs  High endothelial venules 
PLL  Poly- L- lysine 
HRP  Horseradish peroxidase 
PBS  Phosphate buffered saline 
DAB  Diaminobenzidine 
EDTA  Ethylene diamine tetra acetic acid 
TBS  Tris buffered saline 
 
 
